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ABBREVIATIONS 
Term Definition 
ACE Antegrade continence enema 
ARM Anorectal malformation 
ARS Anterior Resection Syndrome 
ASCRS American Society of Colon and Rectal Surgeons fecal 
incontinence score 
CBC Conservative bowel care 
CCCSS Cleveland Clinic constipation scoring system 
CCIS  Cleveland Clinic incontinence score 
CHQ-pf50 Child health questionnaire parent form 
CI Confidence interval 
DH Department of Health 
EAC External Assessment Centre 
EQ5D3L EuroQoL-5D, Quality of life score with 5 dimensions 
FI Faecal incontinence 
FIGS St Mark’s fecal incontinence grading system 
FIQOL Fecal incontinence quality of life (Rockwood et al.,2000) 
ICER Incremental cost effectiveness ratio 
IQR Interquartile range 
ITT Intention to treat 
MAUDE Manufacturer and User Facility Device Experience 
MHRA Medicines & Healthcare products Regulatory Agency 
MS Multiple sclerosis 
MTEP Medical Technologies Evaluation Programme 
NBD Neurogenic bowel dysfunction 
NBDS Neurogenic bowel dysfunction score 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NICE CG NICE clinical guideline 
NICE MTG NICE medical technology guidance 
NICE QS NICE quality standard 
NS Not statistically significant 
PRISMA Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses 
PSLAS Patient symptom linear analogue scale 
QUORUM Quality of Reporting of Meta-analyses 
RCT Randomised Controlled Trial 
SARS Sacral anterior root stimulator 
SBC Standard bowel care 
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SD Standard deviation 
SF-36 Short form health survey-36 
SNS Sacral nerve stimulation 
TAI Trans anal irrigation 
UTI Urinary tract infection 
VAS Visual Analogue Scale  
vs Versus  
WTP Willingness to pay 
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1 Executive Summary 
The company submission contained evidence from one RCT, seven 
observational studies of adult patients and one observational study of 
children. The EAC included a further four observational studies for adults, and 
11 observational studies for children.  
The RCT was a reasonable quality study of 87 adult patients with spinal cord 
injuries. The study reported significant improvements in validated patient 
reported outcomes for bowel function. Where the observational studies of 
adults had comparative data (before and after) there was an improvement in 
in patient reported outcomes for bowel function when using Peristeen. 
Outcome measures such as incidence of urinary tract infections and faecal 
incontinence also improved. Outcomes related to general quality of life 
measures were less widely reported and changes were either not significant, 
or were significantly improved in only some domains. There were 
considerable numbers of patients who stopped using Peristeen, particularly in 
the first few months. 
Evidence for the use of Peristeen in children was based entirely on 
observational studies, with variable quality and less consistent outcome 
measures. General findings indicated that use of Peristeen resulted in 
improvements in bowel management. 
For both adults and children there were variable numbers of patients who 
stopped using Peristeen, particularly in the first few months. This was 
frequently because they disliked using the device, found it painful or 
ineffective.  
The submitted economic model was based on a previously published 
economic model, and finds that Peristeen is both cost saving and cost 
effective in the base case and sensitivity analysis. Cost savings arise from 
reductions in health care staff time, reduced incidence in faecal incontinence, 
urinary tract infections and hospitalisations. The model relies almost 
completely on unpublished audit data and does not make reference to the 
evidence submitted in the clinical submission.  
The EAC found serious errors in the submitted model, correction of these 
reduced the cost saving considerably. The EAC ran additional sensitivity 
analysis to investigate frequency of use of Peristeen, incidence of faecal 
incontinence and the cost and incidence of pressure ulcers.  
The clinical and economic evidence indicates that some patients find that 
Peristeen improves their bowel management. It is likely to be very slightly cost 
saving over a life-time horizon, but there are considerable uncertainties. 
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2 Background  
2.1 Overview and critique of company’s description of clinical 
context 
The company presented a thorough description of bowel dysfunction, 
including the functional forms such as constipation, faecal incontinence and 
obstructed defecation. It also described neurogenic bowel dysfunction, where 
nerve innervation to the bowel is damaged, which can be caused by 
neurological conditions such as spinal cord injury, spina bifida, multiple 
sclerosis, Parkinson’s disease and others associated with impaired or loss of 
sphincter control and bowel mobility disorders. The background information 
provided cites NHS Choices and the NICE clinical guideline CG49, Faecal 
Incontinence in Adults: Management (2007). 
The company’s submission is partially appropriate and relevant to the 
decision problem under consideration. The EAC considers the company’s 
decision to exclude most paediatric studies to be inappropriate, as they are 
included in the scope, and make up over half of the relevant studies found. 
The EAC has included all relevant paediatric studies.  
The device is intended for use by the patient or by a carer. The company’s 
main claimed innovation is that Peristeen has a balloon catheter which holds it 
in place, allowing it to be used hands-free. This is beneficial for patients with 
limited hand dexterity. The company claims that unlike other water-based 
enemas, the Peristeen constant-flow pump is not gravity-based, meaning the 
user does not need to hang the bag up for the irrigant to flow. 
The company present the number of admissions for patients with constipation, 
and estimate the cost. A weighted mean across all finished episodes for any 
cause was used which may not reflect the actual costs of admissions for 
constipation. Not all of these patients would be suitable for Peristeen. 
Figures are also presented by the company for the number of patients with 
faecal incontinence, however not all of these will require, or be suitable for 
treatment with Peristeen. Passananti et al (2016) found that 22% of patients 
with MS and bowel dysfunction were suitable for Peristeen, but this may not 
be generalisable to other patient groups and settings. 
The benefits to patients claimed by the company include improvement in the 
symptoms and frequency of constipation and faecal incontinence, an 
improvement in quality of life for users and a reduction in urinary tract 
infections. 
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Benefits to the healthcare system claimed by the company include reducing 
the rate of stoma surgery, hospitalisation and urinary tract infections in 
patients with neurogenic bowel dysfunction.  
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2.2 Critique of company’s definition of the decision problem, Table 1 
 
Decision problem 
 
company submission 
Matches 
decision 
problem? 
(Y/N/partially) 
 
EAC comment 
 
Population 
 
People with bowel dysfunction in any 
setting. 
Partially The company has excluded paediatric studies 
aside from Midrio et al 2016. This is not an 
appropriate approach, and we have included all 
paediatric studies that were within the scope. 
 
Intervention 
 
Peristeen anal irrigation system. Y  
 
Comparator(s) 
 
Conservative bowel management, which 
can include: 
 diet and bowel habit advice 
 medication (oral drugs, 
suppositories and enemas) 
 disposable pads and anal plugs  
 muscle training/bowel retraining  
 biofeedback and electrostimulation  
 digital stimulation and manual 
evacuation  
It should be noted that the type of 
treatment a person receives is highly 
dependent on their personal preference, 
ability and the carer support available to 
them (see also ‘Cost analysis’ below). 
Y Only one included study was comparative 
(Christensen et al., 2006), employing 
conservative bowel management, which was 
defined as “best supportive bowel care without 
using irrigation. The Paralyzed Veterans of 
America clinical practical guidelines for bowel 
management were recommended”. All other 
included studies are non-comparative.  
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Outcomes 
 
The outcome measures to consider 
include: 
 severity and frequency of 
incontinence and severity of 
constipation using appropriate 
scores (such as Cleveland clinic 
incontinence and constipation 
scores [also known as Wexner 
incontinence and constipation 
scores], St Mark’s faecal 
incontinence score and neurogenic 
bowel dysfunction (NBD) score) 
 quality of life 
 length and frequency of irrigation 
 device-related adverse events 
 frequency of urinary tract infection 
(UTI) 
 incidence of stoma surgery and 
hospitalisations 
 staff time including primary care 
and community care visits 
 individual length of use/user 
satisfaction 
Y Studies have used a wide variety of outcome 
scoring measures, with different degrees of 
validation. The measures used are described in 
table 5 and Appendix C together with 
information on their appropriate use.  
The company have not reported physiological 
outcomes, and the EAC agree that these are 
not in the scope, and would be surrogate 
markers in most cases. 
 
Cost analysis 
 
Comparator(s): Costs will be considered 
from an NHS and personal social 
services perspective. The time horizon 
for the cost analysis will be sufficiently 
long to reflect any differences in costs 
and consequences between the 
technologies being compared. Sensitivity 
analysis will be undertaken to address 
uncertainties in the model parameters, 
Y  
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which will include carer costs, 
patient/carer training costs and costs of 
treating UTI. 
 
Subgroups 
 
 neurological bowel dysfunction 
complications for example 
Parkinson’s disease, stroke, 
multiple sclerosis, spina bifida and 
spinal cord injury 
 bowel dysfunction caused by injury 
e.g. following childbirth 
 slow transit constipation (unrelated 
to childbirth) 
 obstructed defaecation symptoms 
 metastatic spinal cord 
compression 
 low anterior resection syndrome in 
people who have had treatment for 
rectal cancer 
Y All of these indications are covered by the 
included studies aside from: 
 bowel dysfunction caused by injury e.g. 
following childbirth 
 metastatic spinal cord compression 
 
Spina bifida is covered in adult studies with 
mixed populations, and in paediatric studies. 
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Special considerations, including issues related to equality 
Faecal incontinence and constipation can both be related to disability and can 
also both be socially stigmatising. The company does not highlight any 
specific equality-related considerations in their submission. However, the EAC 
believe that the equality issues in the scope have been addressed in the 
company’s submission.  
3 Clinical evidence 
3.1 Critique of and revisions to the company’s search strategy 
The company did not specify if Medline In Process had been searched and it 
was unclear if all the Cochrane Library databases had been searched. The 
search strategy used was not comprehensive and as a result, relevant studies 
may not have been captured. A language limit was applied to the search 
results. The EAC developed a comprehensive search strategy, incorporating 
free text terms and subject headings as directed by the MTEP sponsor 
submission template, which was run across the specified databases as well 
as some others. The company did not search a wide range of ‘grey literature’ 
sources or use supplementary search methods to identify further literature. 
The company tried to identify unpublished studies but did not search any trials 
registers. Details of the company’s and the EAC searches are described in 
Appendix A. 
3.2 Critique of the company’s study selection 
The included studies are all relevant to the use of Peristeen in the adult 
population, and cover a range of conditions for which the device is 
appropriate. However, the exclusion of all but one paediatric studies is not in 
accordance with the scope for this assessment. The company included a sole 
paediatric paper (Midrio et al., 2016) as an “example of best care in the 
paediatric population”, which is not appropriate for an assessment of this type, 
as it is highly likely to introduce bias into the dataset. The EAC do not agree 
that all those excluded did not use validated outcome scoring systems. The 
EAC have included all paediatric studies with relevant outcomes. This gives a 
more complete compliance with the scope. 
3.3 Included and excluded studies 
For the adult population, Chan et al. (2011) was not identified in the company 
search which is relevant to the scope. The device used in the study was not 
specified. The EAC contacted one of the authors who confirmed that the 
device was Peristeen. Nafees et al. (2016) is a discrete choice experiment 
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study that does not directly compare with the other available literature. It is 
likely to contain high amounts of bias as the patients are a self selecting group 
of long term Peristeen users. The EAC included this study in the table to 
provide some useful long term information, but advise that it should be 
interpreted with caution.  
After submission the company clarified that Kim et al (2013) had been 
identified, but excluded. The company did not identify Whitehouse et al. 
(2010) 
Grainger et al. (2017) was identified by the company as a pre-publication 
manuscript and is academic in confidence. 
For the paediatric population the EAC used broader inclusion criteria, and 
therefore all those identified as excluded by the company were included by 
the EAC with the exception of Choi et al. (2015) which used a mix of devices 
and a locally designed questionnaire, and Marte et al. (2013) which reported 
surrogate radiological outcomes only. Marzheuser et al. (2016) was not 
identified by the company. 
A summary of papers included by the company and the EAC is presented in 
tables 2 and 3. 
Although the EAC identified additional relevant papers, these do not change 
the overall direction of the evidence. The RCT is summarised in table 4, all 
other included studies are summarised in appendix B.   
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Table 2: Adult studies included by company and EAC 
KEY:  included,  explicitly excluded, MS Multiple Sclerosis, SB Spina Bifida, SCI 
spinal cord injury, NBD neurogenic bowel disfunction, IC idiopathic constipation, ARS 
anterior resection syndrome, mixed, RCT randomised controlled trial, OBS 
observational, single arm study DC discrete choice experiment, QUAL qualatitive 
interviews included,  explicitly excluded 
Paper  Country Study 
type 
popu-
lation 
n company  EAC 
ADULTS        
Chan 2011 
 
UK OBS mixed 91 -  
Christensen 
2008 
Europe incl 
UK 
OBS# SCI 62   
Christensen 
2006 
Europe incl 
UK 
RCT SCI 87    
Del Popolo 
2008 
Italy OBS SCI 36   
************** ** *** *** ***   
Hamonet-Torny 
2013 
France OBS NBD 16    
Kim 2013 S. Korea OBS SCI 52  -  
Loftus2012 Ireland OBS NBD 11   
Nafees 2016 UK DC mixed 129    
Passananti 
2016 
UK OBS MS 49    
Preziosi 2012 UK OBS MS 30    
Rosen 2011 Austria 
Switzerland 
OBS ARS 14    
Whitehouse 
2010 
UK OBS FBD 113 -  
CHILDREN  
Alenezi 2014 S.Arabia OBS NBD 18    
Ausili 2010 Italy OBS SB 60    
Choi 2015  S. Korea OBS SB 44  
 
  
Corbett 2013 UK  OBS mixed 24    
Kelly 2016 USA OBS NBD 24    
King 2016 Australia OBS SB 20   
Koppen 2017 Netherlands OBS IC 67   
Lopez Pereira 
2010 
Spain OBS SB 40    
Marzheuser 
2016 
Germany OBS ARM 40  
 
-  
Midrio P. 2016 Italy OBS mixed 83    
Nasher 2014 UK OBS IC 13   
Pacilli 2013 UK OBS mixed 23   
#RCT and OBS paper by Christensen use same patients 
Table 3 Adverse event evidence included by EAC or company 
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Paper  Country Study 
type 
popu-
lation 
n company  EAC 
Adverse events only 
Biering 
Sorensen 2009 
Denmark      
Christensen 
2009 
      
Christensen 
2016 
      
Faaborg 2009       
Faaborg 2014       
Economic 
Christensen 
2009 
      
Emmanuel 
2016 
      
In the summary of studies, for each of the design, participants and outcomes entries 
below, the following coding is used: 
 Fully included within the scope 
 Partially included within the scope 
 Not consistent with the scope 
As the scope for this topic is very broad, no single paper is likely to fully encompass 
the scope, however those coded green have participants, and outcomes that are 
included within the scope. 
G 
A 
R 
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Table 4. Summary of RCT, additional studies are summarised in Appendix B.  
Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Christens
en (2006) 
 
RCT comparing 
transanal 
irrigation using 
Peristeen with 
standard bowel 
care (SBC) for 10 
weeks 
Company funded 
Intervention  
Comparator  
87 randomised (42 
Peristeen vs 45 SBC)  
62 men, 25 women 
average age 
49.1years. 
73 completed             
5 European spinal 
cord injury centres 
(Sweden, Italy, 
Germany, UK, 
Denmark)  
All patients 18 years 
or older, at least 3 
months after spinal 
cord injury. 
 
Primary 
outcomes:  
CCCS  and FIGS 
 Secondary 
outcomes: 
NBDS, modified 
ASCRS, numeric 
box score on: 
bowel function, 
influence on daily 
activities and 
general 
satisfaction. 
Outcomes 
collected at week 
0 and 10, plus 
weekly telephone 
interview. 
 
CCCS, FIGS and NBDS were 
significantly improved for 
Peristeen vs SBC. 
Sub-group analysis found no 
significant difference for 
patients who could walk, but 
significant improvement for 
those who used wheelchairs 
or were confined to bed found 
that these  
ASCRS scores were 
significantly improved for 
Peristeen vs SBC in domains 
of coping/behaviour but no 
significant difference for the 
lifestyle and depression/self-
perception domains. 
The numeric box scores were 
significantly improved for 
bowel function, general 
satisfaction and improvement 
in quality of life, but not for 
influence on daily activities. 
14 w/d (12 
Peristeen, 2 
SBC): 
73 completed, 5 
lost to follow-up 
Blinding was not 
possible. 
Large number of 
patients stopped using 
Peristeen before the 
end of the study. These 
were included in ITT 
analysis using baseline 
data in place of missing 
data.  
Baseline imbalance 
between groups for 
number using 
wheelchair or confined 
to bed.  
Sub-group analysis not 
stated as planned. 
Study supported by 
company 
CCCS Cleveland Clinic Constipation Score; FIGS St Mark’s Faecal Incontinence Grading Score; NBDS Neurogenic Bowel Dysfunction Score 
 
 
G 
G 
G 
G 
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3.4 Overview of methodologies of all included studies 
All but one of the studies included are observational case studies. All of the 
studies were reported as full papers rather than as abstracts only. 
The main outcomes are patient reported outcomes. The nature of the device 
is that it is used at home by patients, in many cases without any assistance. It 
is therefore appropriate that the patient reports outcomes that occur at home. 
Some of these outcomes are objective, such as the incidence of faecal 
incontinence, some are more subjective, asking how the patient feels about 
issues. Very few outcomes can be directly measured, and few are recorded at 
the point they occur, and so will be prone to bias. 
No studies are blinded, as this would be impractical for a device of this sort, 
and since outcomes are largely patient reported, there is no possibility of 
blinded assessment. While this may be unavoidable, it is likely to introduce 
bias  
Patient reported outcome measures (PROMS) 
PROMs are questionnaires for self completion by patients to record their 
health, symptoms, functioning etc. Generic instruments are used across a 
variety of patient populations whereas disease or treatment-specific measures 
are used for a particular population. As part of their development, PROMs are 
subject to psychometric testing to show whether they are valid, reliable and 
sensitive to change. Validity is about whether the PROM measures symptoms 
or other concepts that are relevant to patients. Reliability shows whether the 
PROM is consistent over time. 
PROMs are validated in a specific population. The same PROM may not be 
valid when used in a different population or setting, for example, if a PROM 
designed for adults is used for children, the language and context may be 
inappropriate. Generic PROMs may be insensitive to small changes in the 
patient’s condition which are better measured using a condition-specific 
PROM, often in combination with the generic PROM.  
Locally developed questionnaires which have not been subject to 
psychometric testing are unlikely to be valid, reliable or sensitive to change. 
In addition to papers validating each individual score system, there are also 
studies comparing several different outcome measures (Hussain 2012) 
The most commonly used PROMs in the literature concerning Peristeen in 
adults are listed in Table 4. A more complete listing including the PROMS 
used in studies on children is in Appendix C 
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Table 5 PROMS measures with description and validation information. 
CCCS 
Cleveland Clinic 
constipation scoring 
system. Also known 
as Wexner 
constipation score. 
A scale of constipation severity including impact of 
symptoms on the patient’s life. 
 Scores range from 0 to 30, with higher scores representing 
more severe symptoms. 
Widely used, validation compared to physiological measures 
identified.(Agachan et al.,1996). 
CCIS 
Cleveland Clinic 
Incontinence Score. 
Also known as 
Wexner 
incontinence score 
The CCI Score takes into account the frequency of 
incontinence and the extent to which it alters a person’s life. 
. Scores range from 0 to 20, with higher scores representing 
more severe symptoms. 
Widely used, but no formal validation identified. 
(Jorge et al., 1993) 
FIGS or SMFIGS 
St Mark’s fecal 
incontinence 
grading system 
A scale of incontinence severity including the impact of 
symptoms on the patient’s life. 
Scores range from 0-24 with 24 most severe. 
Widely used and validated for use in adults, specific 
diagnoses not specified (Vaizey et al., 1999). 
NBDS Neurogenic 
bowel dysfunction 
score 
Ten questions on bowel dysfunction symptoms. Questions 
do not ask about the impact of symptoms on the patient. 
Scores range from 0 – 47, with 47 most severe.  
 Widely used, validated for use in patients 15+ years with 
SCI. (Krogh et al., 2006). It has also been used in other 
patient groups. Translated into several languages.  
Available on Coloplast website. 
ASCRS American 
Society of Colon 
and Rectal 
Surgeons fecal 
incontinence score 
Symptom related QoL score, with 4 subscales for lifestyle, 
coping behaviour, depression, embarrassment. Each on a 
scale of 0-4 with 4 most severe. 
No information on validation identified. 
SF-36 Short Form 
Health Survey-36 
Generic quality of life score. Self administered or by 
interview. For use in adults 18+ 
Scores 0-100, with 100 as best health. Very widely used, 
and validated (McHorney et al,. 1994) 
EQ5D3L EuroQoL-
5D 
Generic quality of life score. With 243 health states 
descriptive with 5 dimensions, each with 3 levels– mobility, 
self-care, usual activity, pain/discomfort, anxiety/depression. 
Scores are used with a validation set for the appropriate 
country to give a final value of 0-1 with 1 the best possible 
quality of life. 
Patient reported outcome, self administered or by interview. 
For use in ages 12+ 
Generic across clinical areas, very widely used and 
validated. (The EuroQol Group 1990)  
EQ5D-VAS 
EuroQoL-5D Visual 
Anologue Scale 
Scores 0-100 where 100 is perfect health. Part of the EQ5D 
questionnaire. 
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Adult studies 
There was only one randomised controlled trial (Christensen et al., 2006). 
This study employed supportive bowel care as the comparator, which was 
defined as “best supportive bowel care without using irrigation”. The study 
included 87 patients with spinal cord injury and neurogenic bowel dysfunction 
from 5 European spinal cord injury centres, including the UK. The primary 
outcomes measures were the CCCS and FIGS questionnaires. Outcomes 
were collected from patients each week by a researcher who is described as 
not having participated in patient training, but does not appear to be blinded 
as to the intervention. Baseline outcome measures and demographics were 
described for both arms, and it is stated that there was no systematic 
difference in outcomes between the two groups. There appeared to be a 
difference in the mobility of participants (wheelchair use = 29/42 intervention; 
40/45 control) and this is discussed in reporting the outcomes, and also in the 
subsequent study (Christensen et al., 2008). Post-hoc sub-group analysis 
found no significant difference between Peristeen and standard care for 
patients who could walk, but a significant improvement in the Peristeen group 
for those who used a wheelchair or were confined to bed.  
12 patients in the Peristeen arm and 2 standard care patients withdrew from 
the study. Patients who stopped using Peristeen or withdrew before the end of 
the 10 week study were included in intention to treat analysis using a 
termination form for outcome measures, or baseline data in place of missing 
values. There was a significant improvement in CCCS, FIGS and NBDS for 
the Peristeen group compared with standard care. The study is limited by the 
10 week follow-up period, so that it does not record longer term outcomes of 
interest in this assessment. The large number of withdrawals from the study is 
a weakness, but is consistent with the observational studies where patients 
withdraw at an early stage if they do not like the device or find it unhelpful. 
Blinding is not possible, but lack of blinding is a source of potential bias. 
Strengths of the study include the RCT design, the inclusion of a UK centre 
and the intention to treat analysis. Sample size calculations were reported, 
and sufficient sample size reached in the study. The study is described as 
having been supported by the company. 
All the other included studies are observational case series and do not have a 
comparator. One paper was unpublished, but was being prepared for 
publication. Nine of these case series are prospective and three are 
retrospective in design.  
Most studies are small, single centre studies. Outcomes are often subjective 
and may require the patient to recall answers, in some cases up to one year. 
If patients are expected to report on how they felt in the past, there is a risk of 
recall bias. PROM tools often specify the recall time period for the questions, 
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so if these are used retrospectively it may not be valid. The patient 
populations vary in the observational studies; some are of a single condition 
such as multiple sclerosis, whereas other studies include patients with a 
variety of conditions. The observational studies report on inconsistent 
outcome measures, including some locally devised questionnaires without 
validation. Some studies conducted follow-up questionnaires by telephone, 
which may introduce bias, and the telephone interview approach may not be 
validated for the PROM used.  
Studies commonly used sub-groups that appear not to have been pre-
specified in the protocol. Several studies grouped results by those who have 
continued to use Peristeen, compared to those who have ceased or 
alternatively compare “responders” to “non-responders” (Hammonet-Torny, 
2013). This is likely to lead to bias in the results.  
Taken overall the evidence appears to show that adult patients who like and 
continue to use the technology report an improvement in their outcomes. The 
strength of the evidence is weak, and at risk of bias. 
Paediatric studies 
The paediatric studies were non-comparative, observational case series. All of 
the studies were reported as full papers rather than as abstracts only. Six of 
these observational studies are prospective and five are retrospective in 
design. One consisted of qualitative interviews with parents and carers. 
The outcomes for the studies were of two main types, physiological 
measurements, and patient reported outcomes. The company have not 
reported physiological measurements in their submission, and the EAC agree 
with this approach, given that this would be a surrogate outcome for the 
effectiveness of the device and these outcomes are not included in the scope. 
However patient reported outcomes are more difficult to obtain from children, 
as the PROM tools may not be adapted or validated for children of different 
ages. For example the NBDS tool is validated for people aged 15 years and 
over, but in Ausilli et al. (2010) it has been used for a group of patients aged 
8-17 years. It is not always clear in the paediatric studies when parents have 
completed questionnaires and when these have been completed by children. 
Some studies reported patient and/or parent satisfaction.  
The evidence from the paediatric studies is weaker than the evidence for 
adults. This is partly due to the difficulty in obtaining valid PROM data from 
children. The patient populations studied include congenital conditions, such 
as spina bifida, whereas adult patients mainly have acquired conditions. The 
paediatric studies are small, and they report variable numbers who stop using 
Peristeen. The great variety of outcomes reported across the studies, together 
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with the differences in populations and patient ages, makes it difficult to 
combine the results. Some, but not all outcomes in the studies showed 
improvements for children using Peristeen. The quality of the evidence is very 
poor. 
3.5 Overview and critique of the company’s critical appraisal 
The company submitted critical appraisal checklists for all studies that they 
included, using appropriate forms. The company highlighted the differences in 
patient populations between the studies, and the use of a variety of validated 
PROM tools.  
The key study (Christensen et al.,2006), is appropriately randomised, but 
cannot be blinded due to the nature of the device. The company noted that 
data was gathered from patients who withdrew from the study and the 
reasons for withdrawal were discussed. In the critical appraisal checklist the 
company responded ‘yes’ to the question ‘Were the groups similar at the 
outset of the study in terms of prognostic factors, for example, severity of 
disease?’, but the authors of the paper stated that the mobility status of the 
patients at recruitment was different for the two arms. It is clear that the 
outcomes at baseline for the two groups were similar, but the difference in 
mobility status could have led to a ‘no’ response on similarity of prognostic 
factors if mobility status is considered a prognostic factor. 
3.6 Results  
The results have been grouped by studies that are mainly adult or children, 
and by the type of outcome. Tables 6 and 7 summarises the main outcome 
measures used to describe the severity of constipation or incontinence, and 
quality of life. For adults (table 6) there are standardised patient reported 
outcome measures that are used in most papers. For paediatric patients 
(table 7) the reporting uses a wider variety of outcomes and the information 
that can be reported in a table is limited.  
Table 8 shows additional results, including those of key importance for the 
economic evaluation. This includes the number of people ceasing to use 
Peristeen during the evaluation period, the number of UTIs, fecal incontinence 
frequency and adverse events.  
The results for the main outcome measures are generalisable in that use of 
Peristeen is seen to decrease severity of constipation and incontinence 
according to patient reported measures. Some of these measures also 
include an element for the impact on patient lives. Outcomes for generic 
quality of life measures are generally not significantly different before and 
after Peristeen use.  
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Table 6 Main outcomes, adult population 
Study n 
 
follow-
up 
Specific to bowel health / function,  
high score = worse 
General quality of life, high score = better 
CCCS 
0-30 
CCIS 
0-20 
FICS 
0-24 
NBDS 
0-47 
ASCRS 
0-4, 4 
scales 
EQ5D 
0-1 
EQ-VAS 
0-100 
SF-36 
RCT, Peristeen vs CBM  
Christensen 
2006 
42 
vs 
45 
10 
weeks 
10.3 vs 13.2 
p=0.0016 
 5 vs 7.3 
p=0.015 
10.4 vs 13.3 
p=0.048 
Improved  
coping and 
depression 
NS  
lifestyle, 
embarrassm
ent 
   
Before and after studies 
Chan 2011 
 
91 mean 
10.7 
months 
18.72 to 
11.45 
p=0.0001 
16.2 to 10.8 
p=0.005 
      
Christensen 
2008 
62 10 
weeks 
13.4 to 10.2 
p<0.0001 
 8. to 4.5 
p<0.0001 
15.3 to 10.8 
p<0.0001 
    
Del Popolo 
2008 
33 3 weeks non standard questionnaire 
 
non standard questionnaire 
 
Grainger, 
pre- 
publication 
*** *********
** 
************************** ************************** 
Kim 2013 52 6 
months 
non standard questionnaire non standard questionnaire 
discontinuation rate 
Loftus 2012 11 3-28 
months 
19.09 to 
11.54 
p<0.001 
 12.91 to 5.36 
p<0.001 
24.55 to 
14.18 
p<0.005 
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Passananti 
2016 
49 >1 year      All patients: 
0.57 to 0.52 
Users who 
stopped: 
0.57 to 
0.48* 
Continued 
users: 
44.5 to 63.4 
Users who 
stopped: 
44.5 to 41.9 
 
Preziosi 
2012 
30 6 weeks 12 to 8 
p=0.001 
12 to 4 
p<0.001 
     51.3±7.8 to 
50.4±7.8 
p=0.051 
(NS) 
Rosen 2011 14 Median 
29 
months 
 17 to 5 
p<0.01 
  Improved 
 for all 
domains 
  NS physical, 
Improvement 
for mental 
Whitehouse 
2010 
113 mean 
42 
months 
       
PSLAS 
 
adopters vs non-adopters 
Hamonet-
Torny 2013 
16  no baseline data no baseline data 
* no p values reported, 0.57 (95% CI 0.5,0.65) to 0.52 (95% CI 0.4,0.63) for Peristeen, or 0.48 (95% CI 0.16,0.80) for those who stopped using Peristeen. 
Using linear regression to control for confounders such as natural disease progression, found no sig difference with Peristeen 
 
Table 7. Main outcomes, paediatric population 
 
Study 
 
n 
 
 
Follow-
up 
Specific to bowel 
health / function, 
high score = worse 
General quality of 
life,  
high score = better 
 
Additional information 
CCCS 0-30 
CCIS 0-20 
FICS 0-24 
NBDS 0-47 
NBDoS  0-41* 
FiQoL 
SF-36 
CHQ-PF50: 
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Alenezi 2014 18 mean 
49.6 
months 
  3 withdrew (17%) 
15 did not require MACE 
44% stop using pads 
Ausili 2010 60  3 
months 
NBDS: 17.5 to 8.5 
p<0.0001 
 extraction, suppositories, laxatives all down, all p<0.01 
UTI (E.Coli only) 14 to 6 p<0.01 (in 3 month period before and during trial) 
Corbett 2013 24 median 
1 year 
 FiQoL: 40.5 to 51.5 
p<0.0001 
5 withdrew (21%) 
Significant improvement in median: stool frequency/day (3 vs 1), soiling 
per week (14 vs 1), % of bowel motions in toiled (20 vs 100), time 
attending to bowel/day (75 vs 35 min), use of pads 
Kelly 2016 24 6 
months 
NBDoS: 20.21 to 8.83 
p<0.005 
 only 50% had follow up, but all reported as still using Peristeen at 6 
months.  
Koppen  
2017 
67 Median 
11 
months 
  18/67 (27%) had stopped using Peristeen 
Children with occasional FI: 84% prior to Peristeen, 58% after Peristeen 
Marzheuser 
2016 
40 Median 
3 years 
  2 patients discontinued (5%) 
Peristeen use: 12 patients daily; 25 patients 3 times /week; 1 patient every 
5 days. 
79% use Peristeen independently 
Midrio P. 
2016 
83 3 
months 
 SF-36:  sig. 
Improvement in some 
areas (more for SCI 
patients)  
CHQ-PF50: significant 
improvement in most 
areas 
5 withdrew due to difficulty obtaining the device. No other withdrawals 
reported. Improvement reported in constipation, FI, symptoms during 
evacuation, use of laxatives, independence.  
Results are grouped by anorectal anomaly or spinal cord lesion. 
 
Nasher 2014 13 Mean 
21.2 
months 
  3/13 withdrew due to discomfort / did not like procedure (23%) 
Continence score (unvalidated) improved 
None required ACE surgery 
Pacilli 2013 23 Median 
2 years 
  17% stopped using Peristeen 
13% reported discomfort, but still used Peristeen 
Pereira 2010 40 Mean 
12 
months 
  5 did not complete questionnaire 
Significant improvement in non validated questionnaire 
adopter vs non-adopter 
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King 2016 20 Mean 
4.1 
years 
CCCS: 
13.1 vs 10.8 p=0.24 
FICS:  
14.7 vs 16.7 p=0.27 
NBDS  
11.8 vs 12.5 p=0.58 
NS  
92.9 vs 85.2 p=0.28 
55% stopped using Peristeen 
pseudocontinence – 8/9 vs 5/11 
 
 NBDoS range not reported but calculated by EAC to be 0-41. 
Table 8. Additional outcomes relevant to economic model, adult population 
 
Study n Study 
length 
Discontinued at study 
end 
Where reported: FI frequency, UTI, AE, stoma, non SBC interventions, 
hospitalisations, Peristeen, frequency, independance 
Christensen 
2006 
42 
vs 
45 
10 weeks Peristeen: 29% (12/42) 
SBC: 4% (2/45) 
UTI: Peristeen 5.9%, SBC:15.5% p=0.0052 
AE:  PeristeenI: 4 AE (1 PU predating TAI, 1 bowel distention, 1 repeated explusion of 
catheter during training (same patient as PU ) 
Hospitalisations: 3 (2 abdominal pain (1 of these discontinued), 1 PU) 
Peristeen frequency: 6/37 every day, 18/37 every 2 days, 13/37 1-3 times per week 
Chan  2011 
 
91 mean 
10.7 
month 
FI FI: 60% (12/20) 
discontinued  
 
Incontinence: 7/20 
Stoma: 2/20 
Non SBC interventions: 3/20 sphincter repair, 2/20 SNS 
Adverse: 1 patient had constipation and minor rectal bleeding. Discontinued irrigation. 
C C: 50% (25/50) 
discontinued 
 
Christensen 
2008 
62 10 weeks 27% (17/62).  
2 before training,  
5 during training, 
10 during trial 
1 patient withdrew due to adverse events (not stated) 
2 due to insufficient effect 
1 explulsion of catheter 
1 disliked treatment 
1 burst balloon 
Frequency of Peristeen: 20% every day, 48% every second day, 30% 1-3 times per week. 
Del Popolo  
2008 
33 3 weeks 32 completed study FI Frequency: Before: never/rarely is 20/33, After is 28/33 
UTI: 88.9% did not have UTI while using Peristeen 
24 patients said they were less dependent on caregivers 
2 were more dependent 
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6 no variation in dependence 
Frequency of Peristeen: 5 every day, 18 every second day, 10 patients 1-3 times per 
week. 
Grainger 
2017 
*** ******* *******************************
*************** 
******************************************************************************************************
******************************************************************************************************
********************************************************** 
Hamonet-
Torny 2013 
16 Mean 2.6 
years 
4/20 were unable to use.  
62.5% (10/16) still using  
Peristeen frequency:  Mean twice per week 
Independant use: 37.5% independent 
Patients that stopped Peristeen: 
One subocclusive episode that required emergency consultation 
One had vomiting after use  
2 had technical difficulties (takes too long, and one dexterity related) 
Kim 2013 52 6  months 40% (21/52) at 1 month, 
52% (27/52) at 3 months 
65% (34/52) at 6 months 
15 (28.8%) had adverse events 
6/12 compliant patients and 10/24 non-compliant patients reported adverse effects at 1 
month’s use of Peristeen.  
9 abdominal pain, 3 minor anal bleeding, 1 fatigue, 1 perspiration, 1 general discomfort, 1 
perianal discomfort, 1 headache, 1 hot flash. 
Loftus2012 11 3-28 
months 
1/11 wanted not to continue 
post study 
Adverse events: None major during study, I bowel perforation subsequently. Bloating, 
abdominal pain 
Nafees 2016  survey of 
long term 
users only 
n/a FI frequency: 75% had some FI. Episodes in the last month: None 33%, 1-2 43%, 3-4 
16%, 5-6 5%, most days 3% 
UTI: 80/129 had UTIs in last 12 months. Mean of 3.1 in last 12 months.  
Frequency of going to toilet: every 2 days 59%, every day 31%, twice a day 5%, more 5% 
Independent: 71 independent. 89% of those assisted, were by family or friend. 
Passananti 
2016 
49 >1 year 
(mean 40 
months) 
KM plot available.  
36.7 % at 6 months,  
40.7% at 12 months 
UTI: 69 vs 32 in a year 
hospitalisations: 32 vs 19 in a year. Mean length of stay prior was 4.6 days. 
22 had disrupted therapy: 12 (55%) disliked the therapy, 3 (14%) insufficient effect, 2 AEs 
(1 (4%) anal bleeding, 1 (4.5%) abdominal cramps), 1(4%) burst balloon. 
Health care resource use: Reduction in GP visits (27% 186 vs 136), specialist (19% from 
102 vs ), dietician (55% from 32)  
Independent: 44% decrease in dependency on any carer (family / professional)  
Preziosi 
2012 
30 6 weeks 7/37 discontinued/ lost 
before 1st follow up.  
AE: None 
3/16 responders use Peristeen once a week, 13/16 require 2-7 irrigations per week. 
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At 6 weeks, 47% 14/30 
“non-responders” Not 
stated if still using. 
Rosen 2011 14 Median 29 
months 
  
Reduction of defaecations from 8 (4-12) to 1 (1-2).  
Whitehouse 
2010 
113 Mean 42 
months 
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3.7 Description of the adverse events 
Table 9 Summary of evidence for adverse events 
Study Withdrawals AEs Notes 
Christensen et 
al. 2015 
(audit) 
N/A 49 bowel 
perforations 
(across 10 
countries 
audited).  
Bowel perforations: 
35 were certainly caused by 
Peristeen, 7 were “probable” 
and 4 were “possible”. 
This is global audit data, not 
a typical study. 
Christensen et 
al. 2006 
3/4 patients 
who had AEs 
Number of AE = 
4/42 (9.5%). 
These were all in the 
Peristeen group. 
Biering-
Sorensen et al, 
2009 
N/A 1 Single case study on patient 
that had a bowel perforation. 
Faaborg et al, 
2009 
86, only 
10(12%) of 
which due to 
side effects 
of Peristeen 
1 serious AE 
(rectal 
perforation 
requiring 
emergency 
surgery). 
 
 
Bowel perforation is a potential serious adverse event linked to Peristeen use. 
It is a rare complication according to the global audit by Christensen et al., 
(2016). This is based on incidents reported voluntarily to the company and the 
denominator is based upon sales data. Following device alerts from MHRA 
the company changed the IFU and the list of contra-indications. The company 
estimates that these measures have further reduced the risk. Voluntary 
reporting may underestimate the number of events, but since bowel 
perforation is a serious adverse event it is reasonable to expect events to be 
reported. Sales data is a surrogate for the number of procedures undertaken. 
It potentially overestimates the number of procedures as some stock would be 
held, and this would underestimate the risk of bowel perforation. Although the 
absolute figures may be subject to uncertainty, the risk is likely to be 
extremely low. 
Other, less serious adverse events such as abdominal pain, nausea etc. are 
more common, but individual patients are free to choose whether to continue 
using Peristeen or to seek an alternative treatment, and it is clear from the 
evidence that this happens in practice when a proportion of patients try the 
technology but do not continue to use it long term.  
The EAC searched the FDA MAUDE database, and found 62 listings for 
Peristeen, 31 of which were after 2014. Approximately half the total listings 
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were for perforations, and 15/31 (48%) for events post 2014. The most 
common of the remaining events were bleeding and pain. 
3.8 Description and critique of evidence synthesis and meta-
analysis  
The company did not perform a meta-analysis, due to the diverse patient 
population and outcomes reported in the studies presented. The EAC agrees 
with this approach. 
3.9 Ongoing studies 
The company highlighted relevant post-market surveillance data in 
Christensen et al. (2015), but this audit is primarily concerned with adverse 
events only. They also present one academic-in-confidence study which has 
not yet been published, but is in production (Grainger et al.). 
The EAC found two additional relevant studies on clinicaltrials.gov. One is a 
single-armed observation study on Cauda Equina Syndrome patients 
(NCT01784328) which was completed in July 2016. The other is a 
randomised crossover study in patients recovering from bowel cancer surgery 
with Peripheral Nerve Evaluation (PNE) and Peristeen (NCT01313026), which 
is listed as currently recruiting and due to complete in 2019. The two arms 
involve both Peristeen and PNE, and differ only in which of the interventions is 
applied first. 
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4 Economic evidence 
4.1 Published economic evidence 
If published studies are NOT to be included, summarise this succinctly 
and put all details into an appendix.  
Critique of the company’s search strategy 
The company’s search strategy was the same as for the clinical evidence and 
therefore subject to the same limitations. Adding search strings for ‘economic’ 
or ‘cost effective’ did not result in any additional papers. 
Critique of the company’s study selection 
The company included both of the studies identified in their search, which was 
appropriate.  
Included and excluded studies 
Two published economic studies are included in the company’s review of 
economic evidence; Christensen et al. (2009) and Emmanuel et al. (2016). In 
addition the EAC identified two conference abstracts (Emmanuel 2015, 2016), 
but these were from the same model later published by Emmanuel et al. 
(2016) and so do not add any new information.  
The Christensen et al. (2009) model is from the societal perspective, which 
does not match the scope. Therefore the EAC excluded this study, although it 
provides some useful comparison if the societal costs are removed. Although 
the company included this and provided a quality assessment of the study it 
did not include the study in its de novo model. 
Overview of methodologies of all included economic studies 
Christensen et al. (2009) is a cost-effectiveness Markov model based on 
outcomes of a randomised controlled trial at five spinal centres in Denmark, 
Germany, Italy, UK and Sweden. The model by Christensen was from a 
societal perspective with a cycle length of 2 days and a time horizon of 10 
weeks. This very short time horizon means that the model focused on 
differences in UTIs, carer time and products used for bathing and cleaning 
after leakages. Using a societal perspective it also included patient time spent 
on bowel management and the resultant lost salary. Long term outcomes and 
adverse events were not included. 
The economic model provided by the company was the same as that 
described in Emmanuel et al ., (2016), but the company provided more up to 
date prices for comparison with those used in the model. The Markov model 
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had a 6 month cycle and a whole life time horizon of 37 years corresponding 
to the life expectancy of a 30 year old SCI patient. Emmanuel et al. (2016) is a 
cost-effectiveness model based on audit data from three UK hospitals. The 
audit database was set up in 2006.  
Overview and critique of the company’s critical appraisal for each study 
The company completed a quality assessment of the economic studies, but 
critical appraisal is limited.  
Does the company’s review of economic evidence draw conclusions 
from the data available?  
The company did not draw together the information in the published economic 
evidence, although the Christensen et al., (2009) results are referred to 
briefly. 
Christensen et al.,(2009) had lower costs associated with Peristeen for carer 
time for bowel management, frequency of bathing and changing clothes, 
frequency of UTIs and use of constipation medicine compared to SBC. 
However the higher cost of providing Peristeen ( €12/2 days vs no cost for 
SBC) meant that the Peristeen was cost incurring until the value of the 
patient’s lost time was included. 
Emmanuel et al., (2016), more appropriately, had a long time horizon, with 
costs included for outcomes such as the requirement for a stoma. It also 
included adverse events associated with Peristeen, SBC and subsequent 
management strategies. These longer term outcomes and costs resulted in 
Peristeen being cost saving.  
4.2 Company de novo cost analysis 
The company has presented the model from the publication by Emmanuel et 
al. (2016). Clinical inputs are taken from audit data from three UK hospitals. 
Although the model is published, very limited information about the audit is 
included in the published paper. The company has not included data from the 
published studies that were identified in the clinical evidence section. 
The model has a Markov structure, with a variable time horizon representing 
an average patient lifetime, depending on the patient age selected at entry. 
Discounting is 3.5% and an NHS and social care perspective are used. Both 
of these are appropriate. 
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Patients 
The base case is for a male patient, with spinal cord injuries, and 30 years of 
age. While these inputs are variable, the only resulting change in the model 
structure or variables is the time horizon used.  
Inputs to the model are derived from audit data for a heterogeneous group of 
patients including those with spinal cord injuries, multiple sclerosis, cauda 
equina and spina bifida. The model does not include paediatric patients below 
the age of 17 years, and data on these patients are not included in the model 
inputs.  
 Technology 
The technology used in the model is Peristeen, in addition to standard bowel 
care, as required. 
Comparator(s) 
The comparator in the model is standard bowel care. 
Model structure 
The markov diagram provided by the company is accurate, as shown in figure 
1. The submission inaccurately states that patients do not transition directly 
from SBC or Peristeen to stoma, but instead move to other options first. As 
the diagram shows, patients are able to move directly to stoma from all states. 
Once in stoma patients no longer move to any other state. 
The submission also states that death was possible from all states, however 
there is no death state contained in the model. It is assumed that all patients 
survive until the final time horizon. The time horizon is set by an average life 
expectancy table for people with spinal cord injuries, according to the age 
entered by the user. Background mortality rates would normally be included in 
a model with a life time horizon.  
Figure 1, replicating C9.1 from sponsor submission. 
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Key structural assumptions of the model are: 
 All patients enter the model at age 30 and survive for 37 years. There 
is no death state in the model. 
 The probability of ceasing to use Peristeen is assumed to be constant, 
whereas data from published studies (Passananti et al., 2016) shows a 
higher probability of reverting to standard bowel care in the first few 
months of using Peristeen.  
 Adverse events are included, but it is assumed that adverse events are 
reflected as a proportion of the hospitalisations recorded in the audit 
database and in the number of patients discontinuing Peristeen. 
Hospital admissions are assumed to be split equally between 
gastrointestinal infections, pressure ulcers, falls or trauma, abdominal 
pain and UTI. Bowel perforation is not explicitly included. 
 There is a description of patients who are prescribed off-label 
medications (Lubiprostone and Prucalopride, L/P) however these 
patients are not included in any of the model calculations. 
 The model is stated as being for a patient with SCI, and patients are 
assumed to be homogeneous, whereas the audit data is actually made 
up of patients with several different diagnoses, who are likely to have 
different outcomes. 
 The model assumes that variables are constant over time for all 
patients. Many variables are likely to change with age for all patients, 
and will also change over time for patients with progressive diseases 
such as multiple sclerosis. 
 Transition probabilities for patients who start using Peristeen, and then 
revert to SBC are assumed the same as probabilities in the SBC arm. 
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The submission and the model use the terms 1st line, 2nd line and 3rd line, 
which can cause some confusion. Table 10 shows the meaning of these 
terms for each arm. Although the terms imply that most patients will travel 
through each stage, some patients will pass directly to 3rd line or stoma. 
Table 10 Description of states within the model 
 Peristeen arm SBC arm 
1st line Peristeen SBC 
2nd line SBC not available 
3rd line SNS / SARS / ACE (also 
referred to as Surgery) 
SNS / SARS / ACE (also 
referred to as Surgery) 
stoma Stoma Stoma 
Summary of the base case 
The company’s base case is presented in table 11, however the EAC 
identified serious errors in the model that reduce cost saving considerably. 
Table  11 Company’s base case results for 30 year time horizon. 
 Peristeen 
Standard 
Bowel Care 
Cost saving 
per patient 
over 37 years 
Device, training and 
consumables 
£55,135# £29,788 £25,347 
HCP time £45,726 £55,590 -£9,864 
SNS/SARS/ACE costs £6,924 £6,820 £104 
Stoma cost £13,806 £25,917 -£12,111 
adverse events for 
Peristeen / SBC 
£27,061 £52,084 -£25,023 
Subsequent adverse 
events 
£299 £521 -£222 
TOTAL £148,951 £170,719 -£21,768 
#This is the cost of Peristeen plus the cost of SBC for those who returned to 
this treatment option. 
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Clinical parameters and variables 
Audit data 
An audit across three UK hospitals (University College Hospital London, 
Queen Square and Royal National Orthopaedic Hospital Stanmore) was used 
for the majority of clinical and resource use parameters (Emmanuel et al., 
2016). The audit commenced in 2006, and Peristeen was introduced in these 
hospitals in 2007.  
There is a very limited description of the audit data in the economic paper by 
Emmanuel et al., (2016), and also a description of a set of patients with 
multiple sclerosis taken from the same audit (Passananti et al., 2016). The 
company provided an extract of audit data that was used for quality of life 
calculations and also gave information on length of use, and if patients had 
stopped using Peristeen.  
The population studied in the audit was 227 patients aged 17 to 70 years with 
NBD and a variety of neurological diagnoses. At recruitment, patients 
underwent a structured interview, clinical examination, anorectal physiology 
study, quality of life assessment and bowel function questionnaire (NBDS). 
Questionnaires were repeated at each annual follow-up. Resource use data 
was based on patient recall and validated by comparison to electronic patient 
records (Passananti et al., 2016). It appears that recruitment has been 
ongoing for a number of years, with varying lengths of follow up. It is not clear 
if this has been taken into account in analysing the data. 
The comparator (SBC) clinical data was taken from the baseline data for the 
same patients just prior to commencing treatment with Peristeen, except for 
the proportion of SBC patients progressing to stoma. The number of SBC 
patients who have a stoma is taken from retrospective data for 157 patients in 
the database prior to the introduction of Peristeen. These are patients who did 
not receive Peristeen, but would have been eligible for Peristeen. Prior to the 
introduction of Peristeen, patients received standard bowel care.  
The EAC do not have sufficient information to fully critique the audit, or its 
suitability for use in the model. It would seem to be in an appropriate NHS 
setting, with suitable patient pathways and an appropriate, if heterogenous 
population. However, there appear to be differences in the data used for 1) 
the model, 2) Passananti et al., (2016) and 3) an extract provided to the EAC 
by the company. Some differences may be explained by data having been 
taken from a live database at different points in time, however this does fully 
explain all points.  
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The total number of referrals to the three clinics was 350-390 per year since 
2007, but only 227 patients are included as Peristeen users. The other 
patients were not included in the model, but it is not clear if this is because 
they were not suitable for Peristeen, or for another reason.  
Questionnaires were collected annually, but it is not known at what time point 
data for resources was taken. Some patients cease using Peristeen, and 
there is no explanation of how these patients are treated in the data analysis. 
Transition rates 
Transition between the states depends on transition probabilities, derived 
from the audit data, based on the number of observed occurrences at 6 years. 
The EAC do not have full information on the audit, however it is probable that 
the patients are not all enrolled at the same point in time, and therefore at a 
point 6 years after the start of the audit, not all patients will have 6 years’ 
follow up. A survival analysis approach would have been more appropriate. 
This would capture both the varying length of follow-up and give additional 
information on the probability of ceasing to use Peristeen over time.  
Passananti et al.,(2016) published a Kaplan-Meier curve for patients with 
multiple sclerosis demonstrating that dropout rates were higher in the first 6 
months after starting to use Peristeen. This is in accordance with clinical 
evidence presented in table 8 previously, and is likely to be dependent on 
patient preference. The EAC ran survival analysis for the audit data that was 
supplied to them to give a Kaplan Meier curve. Figure 2 shows the effect of 
the constant transition probability in the model, compared to the Kaplan Meier 
curve from audit data, and also compared to three transition probabilities 
values empirically chosen by the EAC to match the KM curve more closely. 
With more certainty in the original data, transition probabilities could be 
calculated more accurately, however the impact of this additional work is likely 
to be small.  
Using a constant transition probability favours Peristeen because more users 
move to SBC at an early stage in the model and so accumulate these costs 
for longer with less discounting. It will also increase the number of procedures 
for SNS/SARS/ACE and stoma. The impact of these changes depends on the 
magnitude of difference between costs for Peristeen and SBC. 
Following enquiries by the EAC concerning calculation of transition 
probabilities the company submitted an amended model.The impact of the 
changes is shown in Appendix E, but the EAC did not consider that the 
changes should be included in the base case. 
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Figure 2 Proportion of patients still using Peristeen after 30 years  
 
The transition probabilities for movement from Peristeen or SBC to 
SNS/SARS/ACE and stoma are calculated in the same way, and it is 
assumed that transitions will be the same for each arm. The EAC did not have 
audit data available to calculate these values. Transition from 
SNS/SARS/ACE to stoma was calculated using GoalSeek function in 
Microsoft Excel, and this was not visible to the EAC. 
Tables 12 and 13 show how many patients are in each of the Markov states 
after 2 years and 30 years for both the base case and the EAC model which 
includes background mortality and variable transition probabilities for 
Peristeen.  
Table 12 Base case submitted by company, showing the number of patients 
receiving each treatment after 2 years and 30 years. 
 Peristeen arm SBC arm 
 2 years 30 years 2 years 30 years 
Peristeen 93% 32% 0% 0% 
SBC 3% 10% 90% 20% 
SNS / SARS / ACE 3% 20% 4% 16% 
stoma 2% 38% 7% 64% 
Dead 0% 0% 0% 0% 
 
   38 of 139 
External Assessment Centre report: Peristeen anal irrigation system 
Date: June 2017 
Table 13. EAC base case showing the number of patients receiving each 
treatment after 2 years and 30 years, using variable transition probabilities 
and background mortality. 
 Peristeen arm SBC arm 
 2 years 30 years 2 years 30 years 
Peristeen 68.7% 13.4% 0% 0% 
SBC 22.4% 3.87% 86.6% 8.7% 
SNS / SARS / ACE 2.6% 8.8% 3.53% 7.2% 
stoma 2.7% 18.2% 6.34% 28.4% 
Dead 3.5% 55.8% 3.6% 55.8% 
Faecal Incontinence 
The mean incidence of faecal incontinence per week for Peristeen (1.5 per 
week) and the comparator (3.5 per week) is referenced to Professor 
Emmanuel. Data was collected as part of the audit, but it is uncertain how this 
was used in model. Faecal incontinence in the model is used to calculate the 
number of anal plugs and incontinence pads required for that proportion of 
patients using them. This is a key driver in the economic model. 
Adverse events  
There are two categories of adverse event in the model: urinary tract 
infections (UTI) that respond to treatment; and events that require 
hospitalisation.  
The incidence of UTI not requiring hospitalisation is assumed to be 0.67 
events per person per year for Peristeen, and 1.37 for SBC. It appears that 
this was derived from audit data but as the source (specified as expert 
opinion) is not made clear in the model, it is difficult to check. Clinical 
evidence summarised in table 8 supports the association of Peristeen use 
with a decrease in UTI events. Bermingham et al. (2013) report for SBC, 0.67 
events per person per year for non-antibiotic resistant UTI, and 0.8 for UTIs 
with first line resistance (neither requiring hospitalisation). 
The rate of admission to hospital also appears to be from audit data and is 
0.28 events per person per year for Peristeen, and 0.63 for SBC. It is 
assumed that the cause of hospitalisations is equally split between abdominal 
pain, GI infection, pressure ulcers, falls or trauma and UTI. Pressure ulcers 
are the event most likely to have an impact on the overall result, as the costs 
are very high in the model. The proportion of readmissions for pressure ulcers 
in patients with spinal cord injuries is reported as 3% (Vaidyanathan et al., 
1998)) and for “skin problems” as 17% (Savic et al., 2000). Given these 
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figures an assumption of 20% seems rather high in the model. Additionally 
both papers report rates of readmission for UTI as just over 40% which is 
higher than in the model. The discrepancy may be greater than this, since the 
model assumes pressure ulcers are grade 4, and the reality may be a mix of 
severity. Both papers are looking at data from nearly 20 years ago, and 
incidence of pressure ulcers may have changed over time.  
Life expectancy 
Alternative ages at entry to the model can be selected and this affects the life 
expectancy which is drawn from a table based on Frankel et al., (1998). This 
publication is almost 20 years old and so may be inaccurate for the current 
population. The life expectancy is used to set the time horizon for the model.  
A recent publication by Savic et al., (2017) has detailed and more up to date 
data for the UK based on 70 years’ of records, however small changes in life 
expectancy will not have a large impact on the model outcome.  
This publication could also have been used to implement background 
mortality in the model. 
Resource identification, measurement and valuation 
Resource identification is a weakness in the submission, due to reliance on 
unpublished audit data, whereas valuation seems to be more thorough. The 
NHS reference codes and costs are not from the most recent data set.  
Prices were not updated to current values where this data was available. For 
example, NHS reference costs for 2015-16 are available. In the submission 
the company lists these for comparison alongside the 2013-14 prices used in 
the model, rather than altering the model. However cost differences are not 
large. 
The resources, costs and calculations for each model input are described by 
the EAC in Appendix D. This gives a weekly cost per patient for each item 
(where appropriate). 
Health care staff time for both arms 
Health care staff time is included for consultant, dietician and GP visits, and 
carer time for bowel care. All of these are taken from audit data which is not 
published and the EAC have no sight of it. The audit data records the number 
of people who had contact with health care professionals and the number of 
visits. For carers, the length of daily carer contact is recorded, however the 
model fails to include it in the calculation.  
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The audit data for health care staff time is based on an annual patient 
interview requiring recollection over the previous year. The submitted clinical 
evidence in table 8 supports some reduction in carer time. 
There are issues with how these costs are included into the model. These are 
discussed in Section 4.5 on EAC changes. 
SNS/SARS/ACE costs 
For ACE, costs for the procedures are created from NHS reference costs, 
using a weighted mean over a number of procedures, with an assumption of 
bi-monthly follow up appointments. The details of these are in Appendix /D. 
SARS uses a price that is for the cost of the device only, however changes 
have little impact on the model. 
For SNS there is a procedure cost and an assumption of an additional 
procedure every 7 years for SNS to replace the battery. The costs are taken 
from NHS England Clinical Commissioning Policy (2013), but the model did 
not include follow up appointments which would be annual after the first year. 
This would have minimal impact on the model result. 
Annual costs of SNS/SARS/ACE in the model, after the initial procedure, are 
lower than costs for either Peristeen or SBC. 
Stoma costs 
Stoma procedure costs are also calculated from NHS reference costs using 
weighted means. They are also in line with costs quoted in the NHS England 
CCP (2013).  
Stoma maintenance costs consist of the consumable items required daily, as 
listed in Appendix D. Clinical advice is that while these are mainly appropriate, 
there will be some differences depending on the patient and the system used. 
Impact of changes is not likely to be high.  
Annual costs of stoma in the model, after the initial procedure, are lower than 
costs for either Peristeen or SBC. 
UTIs 
The model uses a cost of £166.77 per UTI episode, which was originally 
referenced as from Bermingham et al ., (2013) who quote £49 per 
symptomatic UTI event. The manufacturer clarified this as being taken from 
Clark et al (2016). This price is quoted by Clark et al, and referenced as being 
calculated based on Bermingham et al (2013), with no further information 
given.  
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Pressure ulcers 
The company identified adverse events as a key driver of the model. The EAC 
considers in particular the incidence and grade of pressure ulcers and cost of 
treating them is considerable as these are much more costly to treat than 
other adverse events. Uncertainty in the proportion of hospital admissions due 
to pressure ulcers has been discussed in the clinical parameters section. The 
cost used for pressure ulcers in the model is £24,214 for a grade 4 pressure 
ulcer, taken from a report by stoma care nurses (SCN High Impact Action 
Steering Group 2010). This references a report (Touche Ross, 1993) to the 
Department of Health on the cost of pressure ulcers. This is 24 years old now. 
An alternative option would be Dealey et al., (2012) with costs of pressure 
ulcers using bottom-up methodology as below: 
grade 1 - £1,214; grade 2 - £5,241; grade 3 - £9,041; grade 4 - £14,108  
This is a well researched and widely used paper, although prices are 
calculated on the assumption that patients are in-patients already and costs 
are for additional bed-days rather than an admission specifically for pressure 
ulcer. Both studies consider the general UK population rather than patients 
with SCI or any other specific diagnosis. 
The EAC identified issues with adverse events not being included for SBC 
patients in the Peristeen arm, these are discussed in EAC model changes. 
 
Technology and comparators’ costs 
The technology costs for Peristeen and the comparators were taken from the 
NHS drug tariff for 2015, but this is available with up to date prices for 2017. 
Although this is unlikely to have a major impact on the results of the model, it 
would have been better to include current prices 
Peristeen consists of a system that is recommended to be replaced after 90 
uses (6 months if using on alternate days), and a rectal catheter that is single 
use only. Users of Peristeen may still require medications such as bulking 
agents, stimulants, and suppositories. They may also require consumables 
such as anal plugs and incontinence pads. 
Table 14. Annual costs for Peristeen and SBC technologies 
 Peristeen annual 
costs 
SBC annual costs 
System and 
catheter 
£1,712.86# £0 
Training £217.00 one-off cost £0 
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Medication £315.94 £146.32 
anal plug and 
incontinence 
pads 
£1,875.53 £2,483.57 
HCP visits £807.17 £1,046.12 
Carer time £843.80 £1,673.44 
Adverse Events £2,054.63 £4,598.35 
Total:  £7,609.93 
+ initial training 
£217 
£9,947.80 
#assuming Peristeen used once every two days.  
Frequency of use of Peristeen 
The frequency of use of Peristeen is a major driver in the model, and also 
very variable between patients. More frequent use of the device will require 
additional packs of catheters and more rapid replacement of the system. The 
catheter cost has a much larger impact. 
The model assumes that patients will use the device every other day. The 
RCT (Christensen et al., (2006) has the following frequencies 16.2% daily, 
48.6% alternate days, 35.1% 1-3 times weekly. This gives a weighted mean of 
3.5 times a week (or every other day). Looking at other UK studies that report 
these values, Passananti et al., (2016) report a weighted mean of 5.1 uses a 
week for patients with MS, other studies do not report in sufficient detail to 
allow a mean to be calculated. Values are shown in table 8. It is possible that 
as well as a natural variation between individuals, there may be a more 
systematic variation in use for patients with different diagnoses.y model was 
out of date  
SBC medication and products costs 
The model includes costs for required medications such as bulking agents, 
stimulants, and suppositories. The proportion of patients using these is taken 
from the audit data. This is assumed to be at baseline for the SBC arm and on 
follow up for Peristeen patients. It is unknown if the dose is also from the audit 
data, however both doses and costs appear to be appropriate (BNF online). 
The proportion of patients using these medications is different for SBC or 
Peristeen patients, however the doses remain the same. 
In addition there are costs for anal plugs and incontinence pads. These are 
calculated as one per day plus one per faecal incontinence (FI) episode for 
those patients that use them. There is a difference between the proportion of 
patients using these products in the two arms, and there is also a difference in 
the incidence of FI assumed for each arm.  
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Sensitivity analysis 
The company submitted sensitivity analysis that was based on ICERs rather 
than incremental costs. While this may be of interest to the committee, it does 
not address the key concern of cost saving, and may mask the importance of 
some variables to the cost impact of the technology. 
The one way sensitivity analysis submitted appeared to have been from a 
base case different to that submitted, and therefore should not be used. Both 
the one way and probabilistic sensitivity analyses are based on the submitted 
base case prior to correction of errors that were identified by the EAC and 
should not be used. 
4.3 Interpretation of economic evidence 
The company described the strengths of the model as the use of real-life, 
recent data from three UK clinics, and the use of all relevant NHS costs. While 
this is potentially a strength, the lack of transparency of the data and how it is 
used in the model is a major weakness.  
The one-way sensitivity analysis is described as cost saving in all 
eventualities, however the base case submitted has serious errors which 
means this does not hold true. 
The company discuss the impact of frequency of use of Peristeen, which is a 
compound variable from the time to replace the device and the frequency of 
use of catheters. Although the company discuss the replacement of the 
device, it is actually the frequency of use of catheters that is the main driver.  
The company describe the current model as having lower numbers of UTIs 
than in Christensen (2006). This does not appear to be the case in the model 
submitted, however using the UTI rate from Christensen does not make an 
appreciable difference to the incremental cost. 
4.4 Results of EAC analysis 
Due to a number of errors in the submitted model it is not appropriate to 
summarise the results at this point. The EAC interpretation of the results is 
presented in section 4.5 
4.5 EAC Interpretation of economic evidence 
The EAC identified a number of changes that could be made to the model. 
The first section (items 1-8) were considered as corrections where the model 
was not doing what the EAC believe was intended.  
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The majority of these concern how patients that start using Peristeen, but then 
return to SBC are costed: 
In the submitted model these patients had costs included for SBC 
consumables, but not for health care professional visits, additional carer time 
or adverse events (items 2,3). These are the changes that had the largest 
impact. 
Although patients returning to SBC had consumables included, it was at the 
rate calculated for Peristeen. This is inappropriate as these patients are no 
longer using Peristeen, and will be using the SBC pathway (item 4). 
For patients returning to SBC, the incidence of 3rd line treatment or stoma are 
the same in the model. However in calculating the transition probabilities the 
incidence is divided by 7 years for SBC and 6 years for Peristeen (item 5).  
The model description states that the carer time is included at 19 minutes 
daily for Peristeen, and 26 minutes daily for SBC. The model as submitted 
calculated carer costs as 1 hour daily for both arms for the proportion of 
patients who have paid care. Correcting this increased the cost saving for 
Peristeen slightly. 
Items 1, 7 and 8 do not have any impact on the base case incremental cost. 
Table 15. EAC corrections and amendments to submitted model 
 Description Impact on model 
EAC corrections to model 
1 Tornado diagram had not been updated with 
submitted base case.  
No impact on base case.  
Re-run with EAC base 
case. 
2 For patients in the Peristeen arm, who 
return to SBC: The cost of HCP time for 
SBC patients is included. 
Large decrease in cost 
saving 
3 For patients in the Peristeen arm, who 
return to SBC: The cost of SBC related 
adverse events is included. 
Large decrease in cost 
saving 
4 For patients in the Peristeen arm, who 
return to SBC: Costs of consumables used 
by SBC changed to be the same as in SBC 
arm. 
Decrease in cost saving 
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5 For patients in the Peristeen arm, who 
return to SBC: Transition probabilities to 
surgery or stoma are changed to be the 
same as in the SBC arm (based on same 
data).  
Decrease in cost saving 
6 Carer time calculations for both arms 
changed to include the minutes spent daily, 
rather than using an entire hour 
Increases cost saving 
(Peristeen requires less 
carer time in model) 
7 Utility decrements for adverse events 
multiplied by patients in the relevant state 
for both arms. 
No change to incremental 
cost. Very slight reduction 
in incremental utility  
8 Adverse event labeling changed to ensure 
that EAC sensitivity analysis worked 
correctly. 
No change to base case. 
Additional EAC work on model 
9 Variable transition probabilities included to 
model reduction in Peristeen use in first year 
Decrease in cost saving 
10 Background mortality added (Savic 2017) Increase in cost saving 
11 Cost of pressure ulcer changed to £  
£15,134.84(Dealey et al., 2012, £14,108,   
inflated to 2017). 
Decrease in cost saving 
12 Cost of UTI changed to £52.57 
(Bermingham et al,. 2016 (2012), £49 
inflated to 2017). 
Decrease in cost saving 
13 Pressure ulcer cost and proportion of 
readmissions investigated in sensitivity 
analysis 
Likely to decrease cost 
saving. 
14 Frequency of Peristeen use investigated in 
sensitivity analysis 
Highly sensitive to this 
variable. 
The second section (items 9-11) were considered as potential improvements 
in the accuracy of the model. 
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The transition probabilities have been described fully in section 4.2, Clinical 
parameters and variables. The submitted evidence in the Section 3 Clinical 
Evidence suggests that there is a high rate of cessation in the initial months of 
Peristeen use, as some users find it difficult, painful or ineffective. The EAC 
used an extract of audit data supplied by the company to estimate variable 
transition probabilities. This change decreased the cost saving, as more 
patients switched to SBC in the early months. The impact was not large, due 
to the previous EAC corrections that had reduced the cost difference between 
the two treatment strategies.  
Background mortality from all states was added as an EAC investigation into 
the impact. It would typically be included in a model with a long time horizon, 
however the impact was minimal and in favour of Peristeen. The mortality 
rates used were for a population with spinal cord injuries. Although the rate 
would be different for alternative diagnoses, the impact on the model would be 
small.  
Impact on the cost difference between the technology and comparator 
of additional clinical and economic analyses undertaken by the External 
Assessment Centre 
The items are grouped together, as the impact value of any one item is 
dependent on the order in which it is implemented, meaning that a breakdown 
of changes is potentially confusing and misleading. Each change is to a model 
in which the previous changes listed have already been made. 
Table 16. Impact on incremental cost of additional work by EAC 
Model version Incremental 
cost (over 37 
years 
Base Case submitted by company -£21,768 
Changes 1-8: corrections of errors 
 Patients in Peristeen arm returning to SBC have full costs 
including appropriate medication, HCP time and adverse 
events.  
 Carer time in both arms is corrected 
 Transition probability for all patients receiving SBC is 
standardised 
-£7,829 
 
Changes 9-10: EAC suggested refinements 
9. Reduced number of Peristeen users in first year, using 
variable transition probability 
10. Background mortality added 
-£6,976 
11. Pressure Ulcer cost changed to £15,134.84 -£3,574 
12. UTI cost changed to £52.57 -£3,175 
Final EAC base case with all corrections and refinements -£3,175 
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The impact of Peristeen frequency of use, pressure ulcer frequency and 
pressure ulcer cost is also important, however due to uncertainties in the 
correct values, this is investigated in the sensitivity analysis. 
The model is cost saving with the base case, although there are both 
variations in patient groups and uncertainties in data that would lead it to be 
cost incurring in some situations. 
Sensitivity analysis results  
The EAC re-ran both sensitivity analysis after all EAC changes (items 1-12), 
and using incremental cost as an outcome. The tornado diagram in figure 3 
and shows that the main driver in the model is the frequency of use of the 
Peristeen system, with the frequency of faecal incontinence and cost of 
pressure ulcer treatment as other very important factors. The discount rate 
also gives high variations, due to the long time horizon, however this is set at 
a standard rate for all models submitted to NICE.  
Figure 3 Tornado diagram of incremental cost, using EAC base case 
 
 
 
-£10,000 -£5,000 £0 £5,000 £10,000 £15,000
Peristeen use frequency set every 3
days / daily
Discount rate set to 0 / 0,05 p.a
SBC FI episodes set to 2.63 / 4.38
per week
Pressure ulcer cost set to £11351 /
£18919 per episode
Caregiver salary set to £18 / £30 per
hour
Time Horizon  set to 2 years /47
years
Peristeen FI episodes set to 1.13 /
1.88 per week
Low
High
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Table 17 Variables with highest impact in one way SA of EAC base case 
 High Incr.Cost (37 
years) 
Low Incr.Cost 
(37 years) 
Frequency of 
Peristeen use 
Daily £12,229 Every 3 
days 
-£8,115 
SBC Faecal 
incontinence 
4.38 -£4,607 
 
2.63 -£1,743 
 
Cost of 
Pressure 
Ulcers 
£18,919 -£4592 £11,351 -£1757 
The impact of the time horizon is relatively low because almost all of the costs 
of the main strategies accumulate on an ongoing basis, rather than being 
dependant on initial expenditure.  
The one-way sensitivity analysis provided by the company focuses mainly on 
costs of items and does not vary the frequency of their use in the main part. 
The proportion of re-admissions that are for pressure ulcers is not varied in 
the analysis.  
The EAC has investigated this by plotting incremental cost from a range of 
potential costs and re-admittance proportions as shown in figure 4. This 
shows pressure ulcer costs along the x-axis, and plots the incremental cost 
with a given pressure ulcer costs when the pressure ulcers make up 5, 10 and 
15% of re-admissions. As the proportion of pressure ulcers decreases, the 
model structure means that the proportion of UTIs increases. The point where 
all three lines meet is where the cost of pressure ulcers is equal to the cost of 
UTIs, therefore the proportion has no effect. Figure 4 shows that Peristeen 
would be cost saving at a pressure ulcer cost greater than £5,310 for 20% of 
readmissions, or £13,790 for 5% of readmissions, assuming Peristeen is used 
on alternate days and all other variables remain the same.  
Heterogeneity in the patient population has not been recognised in the model. 
The population for the audit data consists of patients with a range of 
neurogenic conditions. It has been observed by Emmanuel et a. (2013) and 
Christensen et al (2006) that outcomes may differ across patients with 
different background. It is also likely that other model variables will differ 
between different patient groups. If sufficient data were available the model 
would be improved by identifying outcomes and variables appropriate to each 
of the wide range of patients who use Peristeen.  
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Figure 4. Incremental cost vs cost of pressure ulcer treatment 
 
The previous diagram assumes that Peristeen is used on alternate days. 
Figure 5 varies the frequency of Peristeen along the x-axis, with lines plotted 
again for the proportion of re-admissions due to pressure ulcers.  
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Figure 5. Incremental cost vs frequency of Peristeen use, shown for different 
proportions of hospital admissions for pressure ulcers. 
 
The assumption of frequency of Peristeen use also has implications for how 
the model responds to sensitivity analysis, as the tornado diagram in figure 6 
shows. Here the base case is set to have daily use of Peristeen. The base 
incremental case is then cost incurring, and due to the difference in costs 
between the two strategies the time horizon becomes increasingly important. 
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Figure 6. Tornado diagram using EAC base case adjusted to show daily use 
of Peristeen.  
 
Probabilistic sensitivity analysis was carried out using the submitted macro on 
the EAC base case for 10,000 runs. The mean incremental cost due to using 
Peristeen was -£3,190, with 73.2% being cost saving for Peristeen use. 
The PSA in the submitted model did not vary frequency of Peristeen use. The 
EAC added this as a probabilistic variable using a gamma distribution, and a 
standard error of 25% of the mean. For the remaining variables the company 
used a standard error of 10% of the mean, however the EAC felt this did not 
reflect a realistic variance in frequency of use. After running the modified PSA 
for 10,000 runs, the mean incremental cost due to using Peristeen was  
-£3,233, with 69.7% being cost saving for Peristeen use. 
Uncertainty relating to transition probabilities is not considered in the PSA, 
these remain fixed throughout the sensitivity analysis. 
Cost Effectiveness 
The submitted model includes cost-effectiveness, using utility values that 
were collected as part of the clinical audit. The utility data from the audit 
shows an improvement in quality of life following treatment with Peristeen. 
The submitted clinical evidence (table 6) for generic quality of life measures 
does not show an overall improvement. However other outcome measures 
that are more specific to bowel management do show improvement, and 
-£10,000 -£5,000 £0 £5,000 £10,000 £15,000 £20,000 £25,000
Peristeen use frequency set every 3 days /
daily
Time Horizon  set to 2 years /47 years
Discount rate set to 0 / 0,05 p.a
SBC FI episodes set to 2.63 / 4.38 per week
Pressure ulcer cost set to £11351 / £18919
per episode
Caregiver salary set to £18 / £30 per hour
Peristeen FI episodes set to 1.13 / 1.88 per
week
Low
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would be expected to add to the user’s quality of life. This is also confirmed by 
the patient expert testimony. 
The PSA, including the EAC modification, was run on the EAC base model for 
10,000 runs. This resulted in the intervention being less costly and more 
effective, and is thus classified as dominant. At a willingness to pay threshold 
of £30,000 Peristeen would be cost effective in 70.5% of cases.  
Figure 7 shows the scatter plot of ICER outcomes that were obtained. 
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5 Conclusions 
5.1 Conclusions on the clinical evidence 
The evidence is composed of one RCT and a large number of observational 
studies mainly of poor quality. The breadth of the scope means that all studies 
are within the scope. 
The company submission contained evidence from one RCT, seven 
observational studies of adult patients and one observational study of 
children. The EAC included a further four observational studies for adults, and 
11 observational studies for children.  
The RCT was a reasonable quality study of 87 adult patients with spinal cord 
injuries treated in five European centres including the UK. Due to the nature of 
the device, blinding of patients was not possible, and there was no reporting 
of data analysis being blinded. In total 14 patients withdrew during the trial, 12 
from the intervention arm (using Peristeen), and two from the comparator arm 
(using conservative bowel management without transanal irrigation). Five 
further patients were lost to follow up. Data was analysed as intention to treat. 
The study reported significant improvements in validated patient reported 
outcomes for bowel function.  
The observational studies of adults were mainly before and after treatment 
comparisons and of variable quality. Eight of the studies included centres from 
the UK, and a further four from Europe. They included patients with spinal 
cord injuries, multiple sclerosis, anterior resection syndrome and functional 
bowel disorder. Where studies were comparative, they all found that Peristeen 
had some improvement in patient reported outcomes for bowel function. 
Outcomes related to general quality of life measures were less widely 
reported and changes were either not significant, or were significantly 
improved in only some domains. There were considerable numbers of 
patients who stopped using Peristeen, particularly in the first few months. 
Evidence for the use of Peristeen in children was based entirely on 
observational studies, mainly of poor quality and less consistent outcome 
measures. The majority (11/12) compared outcomes before and after 
treatment, three were from the UK and five from Europe. They included 
patients with spina bifida, anterior resection syndrome, anorectal 
malformation, hirschsprung’s disease, idiopathic constipation and neuropathic 
bowel dysfunction. General findings indicated that use of Peristeen resulted in 
improvements in bowel management. There were variable numbers of 
patients who ceased to use Peristeen. 
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5.2 Conclusions on the economic evidence 
The economic model relies very heavily on unpublished audit data, meaning 
that the EAC had limited ability to critique or verify it. There remains 
considerable uncertainty in its findings. The clinical evidence submitted was 
not used in the economic model, and does not contain information on longer 
term outcomes such as the need for stomas.  
The EAC made corrections and alterations to the economic model which 
reduced the cost saving due to Peristeen. Following these changes, the EAC 
completed additional sensitivity analysis.  
The cost saving due to use of Peristeen is largely due to reduced time for 
health care professional visits and carer time; reduced incidence of faecal 
incontinence requiring the use of incontinence pads; reduced incidence of UTI 
and fewer hospitalisations.  
The model is very sensitive to the frequency of use, pressure ulcer treatment 
and faecal incontinence, and there is uncertainty about each of these 
variables. There is limited clinical evidence around the frequency of use, and 
for an improvement in faecal incontinence. There is no direct clinical evidence 
linking use of Peristeen to a reduction in pressure ulcers. 
Because the difference in costs between Peristeen and SBC are not large, the 
model is not sensitive to movement of patients between these arms. This 
would not hold true if the base case changed. The ongoing costs of 
SARS/SNS/ACE and stoma (after the initial procedure) are lower than annual 
costs of Peristeen or SBC in the model.  
The model does not recognise the heterogeneity in the patient population 
used to populate the model. The audit data consists of patients with a range 
of neurogenic conditions, and outcomes may differ between these groups. In 
addition the model focuses on patients with neurogenic conditions, however 
there are other groups of patients who use Peristeen. The model results may 
not be generalisable to these patients.  
The EAC corrected model has an incremental cost of -£3,175 when using 
Peristeen over a 37 year time horizon.  
Probabilistic sensitivity analysis with frequency of use included, resulted in 
69.7% % of trials being cost saving when using Peristeen.  
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6 Summary of the combined clinical and economic sections 
The evidence indicates that a proportion of patients find that Peristeen is an 
acceptable treatment that improves their bowel management, while a 
proportion do not continue with its use either because they have difficulties or 
pain in use, or because they find it ineffectual. The economic model relies 
very heavily on unpublished audit data, meaning that there remains 
considerable uncertainty in its findings. The clinical evidence submitted was 
not used in the economic model, and does not contain information on longer 
term outcomes such as the need for stomas. 
The EAC made corrections and alterations to the economic model which 
reduced the cost saving due to Peristeen. The cost saving is largely due to 
reduced time for health care professional visits and carer time; reduced 
incidence of faecal incontinence requiring the use of incontinence pads; 
reduced incidence of UTI and fewer hospitalisations.  
The clinical and economic evidence indicates that some patients find that 
Peristeen improves their bowel management. It is likely to be very slightly cost 
saving over a life-time horizon, but there are considerable uncertainties in the 
model.  
7 Implications for research 
Although the clinical evidence base is not strong, the success of the Peristeen 
anal irrigation system appears to be strongly determined by personal 
preference and circumstances. Patients who find it successful will continue to 
use it, and those who find it ineffectual or painful will stop using it.  
The existing RCT is for patients with spinal injuries only and has a short time 
horizon. This does not capture patients stopping use of Peristeen over time, 
or the number of patients who go on to require further interventions or stomas. 
There is little good quality published evidence on how often Peristeen is used 
in different groups, considering that frequency of use impacts greatly on the 
economic case for Peristeen. Similarly there is little published evidence on the 
impact of Peristeen on susceptibility to UTIs and pressure ulcers across 
different groups. 
Any future studies of Peristeen should carefully record data on the disease 
process underlying the bowel dysfunction, frequency of use, incidence of 
faecal incontinence and complications including UTIs and pressure ulcers.  
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Appendix A Literature search strategy 
Company search methodology 
Databases searched (accessed via NICE/Open Athens portal): 
 EMBASE 
 Medline including with full text 
 PubMed 
 Cochrane database of systematic reviews 
Limits: Jan 2002 – March 2017; English language.  
The specific search terms used were as follows: 
Search Terms 1: Transanal OR retrograde AND irrigation AND bowel 
Search Terms 2: Peristeen 
The outputs of the 2 searches were then merged to form a single database for 
review. 
Unpublished studies were identified through Coloplast and links with the 
clinical community. 
 
EAC search methodology 
The search strategy below was adapted and run in the databases listed in the 
table below. The search was designed to identify clinical, economic and 
adverse event evidence in any language from 2000 to 24 March 2017. The 
databases searched included ones in which conference abstracts are 
indexed. Searches were also conducted of: MAUDE and the MHRA to identify 
notified adverse events; trials registers to identify ongoing and unpublished 
studies; relevant organisations to identify additional ‘grey literature’. 
Supplemenatry search methods included: reference list checking and citation 
tracking of studies included by the EAC in the report. 
Search strategy 
Ovid MEDLINE(R) <1946 to March Week 3 2017> 
1     transanal irrigation.tw. (42) 
2     retrograde continence enema.tw. (0) 
3     transanal colonic irrigation.tw. (4) 
4     Therapeutic Irrigation/ (16616) 
5     peristeen.tw. (15) 
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6     1 or 2 or 3 or 4 or 5 (16625) 
7     Constipation/th [Therapy] (2349) 
8     Fecal Incontinence/th [Therapy] (1730) 
9     Neurogenic Bowel/th [Therapy] (33) 
10     exp Intestinal Diseases/th [Therapy] (45668) 
11     (neuro* adj3 bowel adj (dysfunction or disorder*)).tw. (110) 
12     7 or 8 or 9 or 10 or 11 (47519) 
13     6 and 12 (260) 
14     limit 13 to yr="2000 -Current" (134) 
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Evidence Resource Details 
Date Database Name Database Host Total Number of records 
retrieved 
24/03/17 Medline Ovid 134 
24/03/17 Medline In Process Ovid 8 
24/03/17 Embase Ovid 88 
24/03/17 The Cochrane Library 
CDSR 
DARE 
CENTRAL 
HTA 
NHS EED 
Wiley 12 
1 
0 
11 
1 
1 
24/03/17 Scopus Elsevier 39 
24/03/17 Web of Science Thomson Reuters 81 
24/03/17 EconLit EBSCO 0 
20/03/17 Pubmed NLM 22 
Total number of records from databases after de-duplication =                      209 
27/04/17 MAUDE  62 
24/03/17 MHRA  1 
24/03/17 Clinical Trials.gov  4 
24/03/17 ICTRP  1 
Supplementary Searching 
27/04/17 Coloplast website  3 
(duplicates of database search) 
27/04/17 National Technical 
Reports Library 
 1 
27/04/17 Bladder & Bowel UK  0 
27/04/17 Bowel & Cancer 
Research 
 1 
08/05/17 Citation tracking of key included papers in 
Scopus and Web of Science 
78 
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Flow diagram of EACs study selection 
 
 
 
 
 
 
 
Records identified through 
database searching – duplicates 
removed  
(n =209) 
Additional records identified 
through other sources  
(n =83) plus 62 MAUDE reports; 1 MHRA 
report; 5 clinical trials 
First screen: title/abstract  
(n = 289) 
 
Records excluded  
(n = 194) 
Second screen: assessed 
for eligibility at full text 
(n = 40) 
Full-text articles 
excluded, with 
reasons  
(n = 14) 
Publications 
included in clinical 
evaluation 
(n = 26 full text) 
 
Publications 
included in 
economic 
evaluation  
(n = 2) 
Included: safety 
reports (n=63) & 
ongoing studies 
(n=2) 
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Appendix B Included studies for adults and children 
For each of the design, participants and outcomes entries below, the following coding is used: 
 Fully included within the scope 
 Partially included within the scope 
 Not consistent with the scope 
As the scope for this topic is very broad, no single paper is likely to fully encompass the scope, however those coded green have participants, 
and outcomes that are included within the scope. 
 
 
 
 
 
 
 
G 
A 
R 
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Table B1 Included adult studies 
Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Chan 
(2011) 
Retrospective 
case series of  
Peristeen. 2005-
2009 
Intervention  
Comparator n/a 
91 patients, with 
functional bowel 
disorders. 80 women, 
11 men, median age 
51 (17-78 years). 60 
had constipation, 31 
had faecal 
incontinence.  
 
CCCS, locally set 
level of <15 as 
success. CCIS,  
locally set level of 
<7 as success 
 
Significant improvement in 
CCCS  
Constipation: 83%(50/60) 
were available for follow-up, 
with mean use of 10.7 
months. 25/50 patients 
stopped using Peristeen, 18 
stated this was due to failure 
to control symptoms. 10 
patients had surgery to control 
symptoms. 
Faecal incontinence:65% 
(20/31) were available for 
follow-up, with mean use of 
11.9 months.  12/20 patients 
stopped using Peristeen, 7 
stated this was due to failure 
to control symptoms. 2 
patients had symptoms 
resolved, 7 were offered 
surgery to control symptoms. 
21 were lost to 
follow up. 
Of those patients 
followed up, 37 
had discontinued 
use of Peristeen. 
Large numbers lost to 
follow-up, may 
introduce bias. 
 
G 
G 
G
Ta
bl
e  
   66 of 139 
External Assessment Centre report: Peristeen anal irrigation system 
Date: June 2017 
Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Christens
en (2006) 
 
RCT comparing 
transanal 
irrigation using 
Peristeen with 
conservative 
bowel 
management 
(CBM) for 10 
weeks 
Company funded 
Intervention  
Comparator  
87 randomised (42 
Peristeen vs 45 CBM)  
62 men, 25 women 
average age 
49.1years. 
73 completed             
5 European spinal 
cord injury centres 
(Sweden, Italy, 
Germany, UK, 
Denmark)  
All patients 18 years 
or older, at least 3 
months after spinal 
cord injury. 
 
Primary 
outcomes:  
CCCS  and FIGS 
 Secondary 
outcomes: 
NBDS, modified 
ASCRS, numeric 
box score on: 
bowel function, 
influence on daily 
activities and 
general 
satisfaction. 
Outcomes 
collected at week 
0 and 10, plus 
weekly telephone 
interview. 
 
CCCS, FIGS and NBDS were 
significantly improved for 
Peristeen vs CBM. 
Sub-group analysis found no 
significant difference for 
patients who could walk, but 
significant improvement for 
those who used wheelchairs 
or were confined to bed found 
that these  
ASCRS scores were 
significantly improved for 
Peristeen vs SBC in domains 
of coping/behaviour but no 
significant difference for the 
lifestyle and depression/self-
perception domains. 
The numeric box scores were 
significantly improved for 
bowel function, general 
satisfaction and improvement 
in quality of life, but not for 
influence on daily activities. 
14 w/d (12 
Peristeen, 2 
SBC): 
73 completed, 5 
lost to follow-up 
FIGS is not validated 
for spinal cord injury 
patients. 
Blinding was not 
possible. 
Large number of 
patients stopped using 
Peristeen before the 
end of the study. These 
were included in ITT 
analysis using baseline 
data in place of missing 
data.  
Baseline imbalance 
between groups for 
number using 
wheelchair or confined 
to bed.  
Sub-group analysis not 
stated as planned. 
Study supported by 
company 
G 
G 
G 
G 
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Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Christens
en (2008) 
Prospective 
before and after 
study of 
Peristeen with 10 
weeks follow-up. 
2003-2005. 
Intervention  
Comparator n/a 
62 patients with spinal 
cord injury and 
neurogenic bowel 
dysfunction. 45 men 
and 17 women, mean 
age 47.5 years, from 5 
European centres. 
42 patients used 
Periseteen for 10 
weeks as part of 
Christensen 2006  
RCT. 20 additional 
patients used 
Peristeen for  10 
weeks, after having 
CBM as the control 
group in the RCT. 
 
CCCS, FIGS, 
NBDS  
Patients were 
contacted each 
week during 
follow-up to 
complete a short, 
structured 
questionnaire. 
Mean CCCS, FIGS and 
NBDS improved significantly 
from  baseline to 10 weeks  
 
17 withdrew:  
2 withdrew before 
training,  
5 during training, 
2 because of 
insufficient effect, 
1 due to 
expulsion of 
catheter,  
1 disliked 
treatment,  
1 due to burst 
rectal balloon,  
1 because of 
adverse events,  
4 lost to follow-
up. 
The same patients 
were also in the 
Christensen (2006) 
paper. It is not clear 
why only 20 patients 
from the total of 45 in 
the control group were 
included.  
FIGS is not validated 
for spinal cord injury 
patients. 
ITT analysis, 10/17 had 
assessment at point of 
withdrawal, 7/17 used 
baseline data for 
outcomes. 
Study results found 
greater improvement 
for patients with 
mobility, contradicting 
sub-group results for 
Christensen 2006. Also 
variability in outcomes 
between study centres. 
G 
G 
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Del 
Popolo 
(2008) 
Prospective 
multi-centre 
before and after 
study of 
Peristeen. 3 
weeks treatment. 
Data analysis 
supported by 
company. 
Intervention  
Comparator n/a 
33 patients with spinal 
cord lesion and 
severe neurogenic 
bowel dysfunction 
(NBD) from 10 centres 
in Italy. 18 men and 
15 women, mean age 
31.6 years. The cause 
of the spinal cord 
lesions were: trauma 
14, spina bifida 12, 
MS 2, surgery 1, other 
3, not recorded 1. 
A newly devised 
questionnaire  in 
Italian assessing 
QoL in NBD. 
Covering urinary 
function, bowel 
function, NBD, 
QoL. 
 
Significant improvement in: 
feeling of incomplete 
evacuation, abdominal pain, 
leakage of faeces, gas 
incontinence, time for 
evacuation, patient opinion of 
intestingal function, Quality of 
life score and satisfaction.  
Following treatment 24 
patients considered they were 
less dependent, 2 were more 
dependent and 6 reported no 
change. 
1 w/d lost to 
follow-up. 
The questionnaire was 
not validated. It was 
designed by experts. 
There appears to be no 
patient involvement in 
the design of the 
questionnaire. 
Heterogeneous patient 
group. Small patient 
numbers across a large 
number of centres. 
Questionnaire not 
available, possibility of 
selective reporting of 
outcomes. 
Results are not given in 
detail. 
G 
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Grainger 
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Hamonet
-Torny 
(2013) 
Retrospective 
before and after 
study of 
Peristeen 
Intervention  
Comparator n/a   
16 patients with NBD 
from 1 centre in 
France. 10 women 
and 6 men, mean age 
49 years. Underlying 
neurological pathology 
was: spinal cord 
injury***), MS (4), 
cerebral palsy (2), 
spina bifida (2), cauda 
equine syndrome (1), 
stroke (1), multiple 
system atrophy (1).  
From 2010. 
CCCS,NBDS, 
satisfaction with 
peristeen and 
training using a 
score 1-10.  
All conducted by 
telephone 
interview. 
62.5% still using Peristeen 
after 2.6 years  
For 10/16 who continued use: 
No significant difference in 
laxative consumption after 
treatment. 
77.8% of patients reported 
technical problems. 85.7% 
were balloon bursts. 
Mean patient satisfaction 
9.12/10. Mean satisfaction 
with education 8.66/10. 
1 AE, occurrence of 
rectorragia at beginning of 
treatment. 
For patients who stopped 
using Peristeen:1 
subocclusive episode 
requiring emergency 
consultation. 
6 w/d (4 at 
1month, 1 at 3 
months, 1 at 23 
months, mean 5 
months) 
2 patients found it 
too time 
consuming or 
difficult to use 
1 vomiting after 
administration 
3 stopped 
because of 
inefficacy.  
 
The first patients in the 
centre to use the 
device. Possible 
learning curve effect. 
Small patient group. 
Main outcomes not 
compared to baseline 
data. 
Outcomes reported 
only for those who 
continued with the 
treatment (10/16). 
High risk of bias. 
 
 
G 
G 
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Kim 
(2013)  
 
 
Prospective 
observational 
study of 
Peristeen 
Intervention  
Comparator n/a 
52 patients with NBD 
secondary to SCI 41 
men and 11 women, 
mean age 44.5 years, 
from 3 hospitals in 
South Korea.2010-
2012. 
A locally 
designed 
questionnaire 
administered by 
telephone 
interview at 1, 3 
and 6 months 
after initiation of 
Peristeen. 
33/52 reported problems at 1 
month. Most common was 
expulsion of catheter (n=25). 
adverse effects (n=15), 
abdominal pain was most 
common (n=9). 
34 withdrew. 
Use of Peristeen 
was 31 (59.6%) 
at 1 month, 25 
(48.1%) at 3 
months and 18 
(34.6%) at 6 
months. 
 
Post-hoc comparison of 
compliant with non-
compliant patients 
introduces bias.  
Outcomes are not 
validated. 
The study was partly 
supported by Coloplast 
Korea. 
Loftus 
(2012) 
Prospective 
before and after 
study of 
Peristeen with 
follow-up at 
varying times 
between 3 and 
28 months. 
Intervention  
Comparator n/a 
11 patients with a 
spinal cord injury 
(n=9) or spina bifida 
(n=2) and neurogenic 
bowel dysfunction 
from a single centre in 
Ireland. 4 women and 
7 men, mean age 44 
years. 2007-2009 
CCCS, FIGS, 
NBDS  
Adverse events. 
Mean CCCS, FIGS and 
NBDS significantly improved 
from baseline to follow-up.  
Significant reductions in 
bloating (p<0.05) and 
abdominal pain (p<0.01)  
Adverse events included burst 
balloons (n=NR). 1 patient 
suffered a clostridium difficile 
infection. 
Authors noted that after the 
study period, one patient had 
a perforated bowel resulting in 
sepsis leading to treatment in 
intensive care and colostomy.   
0 w/d 2 (of 11) patients 
completed the baseline 
questionnaires 
retrospectively after 
treatment had started. 
Variable follow-up 
periods. 
Very small study size. 
G 
G 
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Nafees 
(2016) 
Prospective 
discrete choice 
study for patients 
from a panel of 
Peristeen users. 
Survey 
completed online. 
Intervention  
Comparator n/a 
143 UK participants, 
48 with SCI, 69 with 
MS, 12 with SB, 14 
excluded. Mean 
duration of condition 
18.7 years.  
Locally written 
DCE, plus CCCS 
and FIGS, 
EQ5D3L 
98% of patients surveyed 
currently use Peristeen, with 
42% using for 4+ years. There 
are no comparative results 
reported. 
The most important attributes 
for patients were FI (OR 
5.18), risk of UTIs (OR 3.43) 
and frequency of use (OR 
4.69). 
14 excluded due 
to failure on 
consistency 
check 
Patients chosen from a 
panel of peristeen 
users may introduce 
selective bias. Data 
only from people who 
are committed users of 
device, but does give 
longer term information 
SD is large for some 
outcomes, variability 
between patients. 
Data is patient 
reported, in some 
cases requiring recall 
over the last year. 
G 
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Passana
nti (2016) 
Prospective case 
series with a 
minimum 1 year 
follow-up. 
Consecutive 
recruitment 
Intervention  
Comparator n/a 
49 patients with 
Multiple Sclerosis 
(MS) were treated 
with Peristeen, 2008-
2013. 37 women 
(76%),12 men (24%), 
mean age 51 years, 
from 2 UK centres. 
All patients were over 
18 years with a 
confirmed diagnosis of 
MS and neurogenic 
bowel disease for at 
least 6 months. 
Comparison with data 
from year prior to 
introduction of 
Peristeen. 
Additional 
comparisons between 
patients who 
continued to use 
Peristeen and those 
who stopped. 
Anorectal 
physiology, 
EQ5D3L,  EQ-
VAS, NBDS 
scores, resource 
utilisation (patient 
reported). 
Mean EQ5D utility declined 
over time for all patients.  
Patients continuing to use 
Peristeen showed an increase 
in EQ-VAS from 44.5 at 
baseline to 63.4 at latest 
follow-up. Patients who 
stopped using Peristeen 
showed a decline in EQ-VAS 
from 44.5 to 41.9. 
Patients who continued with 
Peristeen improved their 
NBDS scores, with a shift 
from more to less severity. 
Reduction in UTIs per year, 
number of hospitalisations, 
need for assistance, and visits 
to GP, specialist or dietician.  
22 w/d from 
Peristeen 
treatment. 
12 disliked 
treatment,  
3 reported 
insufficient effect 
2 developed 
adverse events, 
1 technical 
problems (burst 
balloon,  prior to 
2011 design 
change),  
2 developed 
other pathology 
preventing 
irrigation, 
2 lost to follow 
up.  
Using the patients who 
discontinued Peristeen 
as a comparator group 
introduces selection 
bias. Potentially those 
where MS has 
progressed more are 
more likely to cease 
use, and would 
therefore have lower 
scores over many 
areas. 
Duration of follow-up 
was variable with a 
mean of 40 months. 
G 
G 
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Preziosi 
(2012) 
Prospective 
before and after 
study of 
Peristeen with 6 
weeks’ follow-up.  
Intervention  
Comparator n/a 
30 patients with MS 
from a single UK 
centre. 
CCCS and CCIS 
(described in 
paper as Wexner 
Constipation 
score; Wexner 
incontinence 
score); SF-36 
Telephone 
interview at 3 
months and 6 
months for those 
still using 
Peristeen. 
CCCS and CCIS improved 
significantly baseline to 6 
weeks  
No significant improvement in 
SF-36. 
 
7 w/d prior to use 
of Peristeen 
4 patients 
withdrew after the 
training session,  
1 experienced 
worsening of MS 
and stopped 
irrigation,  
2 were lost to 
follow-up. 
No information on 
withdrawals after 
Peristeen was 
started. 
In post-hoc analysis the 
cohort was split into 16 
‘responders’ (at least 
50% improvement in at 
least one of the  
Wexner scores) and 14 
‘non-responders’. 
3 month and 6 month 
follow up only reported 
for responders. 
Patients withdrawing 
before use of Peristeen 
were excluded from 
analysis.  
Patients who ceased 
use of Peristeen were 
included as ITT. 
Rosen 
(2011) 
Prospective 
before and after 
study of 
Peristeen 
Intervention  
Comparator n/a 
14 patients with 
anterior resection 
syndrome (ARS) 
following surgery for 
rectal cancer from 2 
centres, 1 in Austria 
and 1 in Switzerland.  
11 men and 3 women, 
median age 68 years. 
Median follow-up 29 
months.2006-2009. 
SF-36, ASCRS 
questionnaire, 
Cleveland 
incontinence 
score (CIS). 
Mean CCIS and ARCS was 
significantly improved.  
SF-36 significantly 
improvement in the mental 
component. No significant 
difference for physical 
component.   
Significant decrease in mean 
defaecations during day and 
night.  
****** SF-36 not reported as 
overall score. 
Small number of 
patients. G 
G 
G 
G 
G 
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Whitehou
se 2010 
Prospective case 
series 
Intervention  
Comparator n/a 
113 patients with 
functional bowel 
disorder (FBD), 96 
female, 17 male. 
Mean age 54.7 years 
(range 17-83 years. 
Mean length of follow 
up 42 months (7-84 
months). Single centre 
in UK. 2001-2009. 
 
  
 
FIGS, patient 
symptom linear 
analogue score 
(PSLAS), history 
of frequency, 
success, use of 
laxatives. 
Follow up at 6 
week, 3 month, 6 
month, 12 month, 
varied according 
to patient need. 
 
Significant improvement in 
PSLAS score for all patients, 
and sub-groups of patients, 
grouped by main symptom of 
FI, Constipation and 
evacuatory disorder.  
 
Other results were not 
reported. 
152 initially 
identified, but 39 
did not receive 
Peristeen, or 
were lost to 
follow up. These 
were not 
included. 
 
 
High risk of bias in 
results as one of main 
outcomes not reported. 
No ITT used, not known 
which of 39 excluded 
patients received 
treatment. 
Unclear if patients are 
still using Peristeen, or 
at what time point 
results were recorded. 
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Alenezi 
(2014) 
Prospective case 
series of 
Peristeen from 
2006-14. 
 
18 children due to 
undergo 
reconstructive bladder 
surgery and the 
Malone antegrade 
continence enema 
(MACE) procedure 
11 girls, 7 boys, 
average age 7.6 years 
(range 4-15) 
From a single centre 
in Saudi Arabia 
 
Successful 
response to 
Peristeen defined 
as complete 
dryness from 
stool soiling with 
minimal or no 
constipation. 
Diaper 
independency, 
patient and 
parent 
satisfaction, 
weekly frequency 
of Peristeen use 
Mean post-operative follow-
up 49.6 months  
15 patients (83%) had a 
successful response, and 
had bladder surgery without 
MACE.3 patients(17%) had 
a poor response. 
8 patients (44%) were able 
to stop using diapers. 1 
patient had difficulty 
retaining the Peristeen 
system in the rectum during 
use, 4  patients had mild 
transient abdominal 
discomfort. 
 3 patients did not 
use Peristeen 
Limited baseline data 
on participants. Limited 
reporting of results. 
Small sample 
Ausili 
(2010) 
Prospective 
observational 
before and after 
study of 
Peristeen with 3 
months’ follow-up 
60 children with 
myelomeningocele 31 
boys and 29 girls, 
mean age 12.5 years 
(range 8-17) referred 
to a single centre in 
Italy. 
NBDS, patient 
satisfaction, time 
for bowel 
function, use of 
oral laxatives, 
use of manual 
extraction, 
frequency of 
urinary tract 
infections (UTI), 
adverse events 
Significant improvement in 
mean NBDS, use of manual 
extraction, suppositories or 
enemas and use of oral 
laxatives, frequency of UTI.  
No severe AE recorded. 
2 w/d (62 started 
the study). 
Short follow up time. 
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Corbett 
(20114) 
Retrospective 
case note review 
of Peristeen from 
2006-2013 and 
quality of life 
assessment.  
24 children with faecal 
incontinence 
secondary to 
myelomeningocele 
(15), Hirschsprung 
disease (4) and 
anorectal 
anomalies(5). 13 boys 
and 11 girls, median 
age at consent 6 
years (range 4-16) 
from 1 UK centre . 
Interview with 
primary carer 
using FICQOL 
questionnaire 
Stool frequency 
Frequency of 
incontinence 
Proportion of 
motions in toilet 
Need for pads to 
control 
incontinence of 
stool, impact on 
child and carer’s 
lives. 
Median follow-up was 1 year  
Significant improvement in 
median for: quality of life, 
stool frequency, soiling 
frequency, proportion of 
motions in the toilet, time 
attending to bowel habit.  
Of those using Peristeen at 
the end of the study, the 
number using pads fell 
(18/19 vs 10/19) Only 3/19 
used the device entirely 
independently. 
3 w/d almost 
immediately, due 
to burst balloon, 
abdominal colic or 
dislike of system. 
A further 2 
patients stopped 
using the device  
as its use failed to 
improve 
continence.  
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Kelly 
(2016) 
Prospective 
observational 
before and after 
study of 
Peristeen with 6 
months’ follow-up 
24 patients with NBD 
secondary to spina 
bifida, 11 male and 13 
female, mean age 
10.5 years (range 3 – 
21)at a single centre 
in the USA. 2014-
2015. 
NBDoS at 
baseline and 2 
weeks, 2 months 
and 6 months 
after Peristeen 
started. 
Significant improvement in 
mean NBDoS at 2 weeks, 2 
months and 6 months.  
 
24 (100%) 
NBoDS scores 
were recorded for: 
24/24 (100%) at 2 
weeks,  
10/24 (42%) at 2 
months  
12/24 (50%) at 6 
months.  
All patients 
reported 
continuing to use 
the device at 6 
months. 
Most common reasons 
for lack of follow-up 
were reported as 
difficulty attending 
appointments or 
disconnected phone 
lines. 
16/24 patients were 
using cone enemas 
prior to Peristeen. 
NBDoS validated for 
paediatric patients 
Range of scores was 
calculated by EAC to 
be 0-41 based on 
reported questionnaire. 
King 
(2016) 
Retrospective 
case series with 
questionnaires of 
Peristeen 
between January 
2006 and July 
2013 
33 patients with spina 
bifida in whom 
Peristeen was tried 
were identified. 20 
families could be 
contacted and 
interviewed. Of the 20 
children 11 were boys 
and 9 girls, mean age 
14.5 years (SD 5.3). at 
time of follow up. 
Patients treated at 2 
centres in Australia. 
FIQOL,FIGS, 
CCCS, NBDS 
Mean follow-up was 4.1 
years (range 1-8 years). 
No significant difference in 
FIQOL,FIGS, CCCS, NBDS 
between those still using 
Peristeen and those who 
stopped. 
11/20 patients 
(55%)  had 
stopped using 
Peristeen 
Comparison of those 
still using Peristeen 
with those who stopped 
using it is biased. 
Large proportion who 
could not be contacted 
introduces further bias. 
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Koppen 
(2017) 
Cross-sectional 
study between 
March 2014 and 
October 2014 
67/91 parents of 
children with 
intractable functional 
constipation treated 
with Peristeen. 
Mean age of children  
11.2 years (4-19yrs) 
Use of Peristeen, 
gastrointestinal 
symptoms, 
concomitant 
medication use, 
parental 
satisfaction,  
Median duration of use 11 
months (1 – 36 months). 22  
(33%) children used daily, 
15 (22%) used it every other 
day, 18 (27%) had stopped 
use. 50% of children used 
concomitant medication. 
Prior to treatment 56 (84%) 
children had occasional 
episodes of faecal 
incontinence which had 
resolved completely in 28 
(42%) after treatment, 8 
(12%) had < 1 episode/week 
and 47% ≥1 episode/week. 
28 (42%) children 
experienced pain. 
38 (57%) parents reported 
that rectal irrigation was a 
feasible treatment. 45 (67%) 
reported that would continue 
with Peristeen use. 
24/91 (26%) 
parents did not 
respond to 
survey. 
18/67 (27%) had 
stopped using 
Persisteen 
Questionnaire was not 
validated. Single 
centre. 
Differences between 
users and non-users 
not investigated.  
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Marzheu
ser 
(2016) 
A prospective 
case series of 
Peristeen with up 
to 4 years’ follow-
up. 
40 children with 
incontinence and 
faecal soiling 
secondary to 
anorectal 
malformations, mean 
age 10.95 years at a 
single centre in 
Germany. 
18 patients as 
comparative cohort, 
using other irrigation 
methods (gravity, 
electric pump, foley 
catheter) Median 
duration 3 years (1-4 
yrs) 
Soiling, time 
needed for 
irrigation, time 
interval between 
irrigations 
At 12 months, 32 patients 
(80%) were free from soiling. 
Significant improvement in 
median soiling frequency 
and time for irrigation.  
The median number of 
irrigations per week fell (7 vs 
3, p<0.001). 
30/38 were using Peristeen 
independently(79%). The 
remainder were all younger 
than 7 and needed at least 
some help from carers. 
2 patients did not 
follow the 
therapeutic 
regime. 
Comparative cohort is 
out of scope. 
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Midrio 
(2015) 
A prospective 
observational 
before and after 
study of 
Peristeen with 3 
months’ follow-up 
83 patients were 
recruited and 78 
completed (41 with 
anorectal 
malformations and 37 
with spinal cord 
lesions) aged between 
6-17 years from 8 
centres in Italy. 
Bristol stool 
score, Local, 
unvalidated 
questionnaire for 
bowel function, 
Quality of life 
using SF36 and 
CHQ-pf50. 
Adverse events. 
Improvements in 
constipation, incontinence, 
symptoms during 
evacuation, daily 
incontinence to flatus, use of 
laxatives, evacuation on 
lavatory and need for carer 
assistance. Significance was 
not reported. 
QoL significant 
improvements for: 
Younger patients: most 
components of CHQ-pf50  
For 12-17 yr olds, 
usingSF36: 
SCI group: significant 
improvement for all aspects 
except bodily pain (9/10).  
ARM group: only bodily pain, 
physical component and 
mental component (3/10) 
showed significant 
improvement. 
Most frequent complications 
were burst balloon, faecal 
leakage during irrigation, no 
useful effect and balloon 
expulsion. 
5 w/d due to 
difficulty obtaining 
device through 
national health 
system. 
SF36 is intended for 
adults aged 18+  
CHQ-pf50 is validated 
for children >5 years, 
but should report 
summary statistics not 
separate outcomes. 
Significance not 
reported for all 
outcomes.  
   82 of 139 
External Assessment Centre report: Peristeen anal irrigation system 
Date: June 2017 
Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Nasher, 
2014 
Retrospective, 
case series. 
Mean follow up 
21.2 ±0.9 
months. 
13 patients referred to 
a single UK centre 
who would otherwise 
been offered ACE 
surgery, 10 treated 
with Peristeen. 7 boys, 
3 girls. 7 with chronic 
idiopathic constipation 
(CIC), 2 with 
Hrischsprung’s 
disease (HD), 1 with 
anorectal 
malformation (ARM). 
Mean age 11.1 ±2.7 
years. 2010-2012 
Faecal 
continence 
scoring system 
by Rintala 1995,  
Mean length of use of 
Peristeen 12.6 months, 
mean follow up 21.2 months. 
Significnant improvement in 
mean Rintala score.  
No complications recorded, 
no patients required ACE 
procedure. 
3 xcluded as 3/13 were 
excluded as they 
found procedure 
uncomfortable or 
disliked it. 
Continence score 
reported as validated,  
but validation method 
not identified in paper. 
No rationale for using 
this scale given. 
Patients with 
neuropathic bowel 
dysfunction excluded. 
Pereira 
2010 
Prospective 
before and after 
observational 
study of 
Peristeen. Mean 
follow up 12 
months (4-8) 
40 children with spina 
bifida and neuropathic 
bowel dysfunction 
enrolled in a single 
centre in Spain. 35 
completed study, of 
which 18 boys and 17 
girls. Mean age 12.5 
years (range 6-25). 28 
patients had 
myelomeningolcele. 
Locally designed 
questionnaire  
Significant improvements in 
all aspects of questionnaire 
– pain, feeling of incomplete 
evacuation, 
sweating/headache during 
defecation, leakage of 
faeces. 
These are not comparable to 
other studies, as non-
standard questionnaire. 
5 did not 
complete the 
questionnaire 
 
Non-validated 
questionnaire. No 
information on reason 
for 5 withdrawals.  
Time point for 
questionnaires not 
stated. 
Paper describes 
patients as children, but 
ages are up to 25 
years. 
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Included 
studies 
Design and 
intervention(s) 
Participants and 
setting  
Outcomes Results Withdrawals EAC Comments 
Pacilli, 
2014 
Retrospective 
case series of 
treatments over 5 
year period. 
23 children treated at 
a single centre in UK. 
Median age at start 
was 7 (2-15) years. 
Median follow up 2 
(0.7-3.4 years). 
Diagnoses were 11 
with spina bifida, 6 
with anorectal 
anomaly, 1 with 
Hirschsprung’s 
disease, 5 with other 
complex anomalies. 
2007-2012. 
 General 
satisfaction, side 
effects during 
treatment, use of 
laxatives. 
17% (4/23) stopped using 
Peristeen due to difficulties 
and pain on insertion of 
catheter and expulsion of 
catheter during irrigation 
(n=2), persistant soiling 
(n=2), requirement for more 
than 2 uses daily (n=1). 
13% (3/23) reported mild 
discomfort and abdominal 
pain, but remained using 
Peristeen. 
No serious adverse events 
relating to Peristeen were 
reported. 
4 stopped using 
Peristeen during 
study period, due 
to: 
Difficulty/pain 
(n=2), 
Persistant soiling 
(n=2), 
Need 2+ uses 
daily (n=1). 
No validated survey 
used. 
Very limited reporting of 
outcome results, and 
collection methods. 
Before and after 
comparisons not 
reported. 
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Appendix C Patient reported outcome measures 
CCCS 
Cleveland Clinic constipation 
scoring system. Also known as 
Wexner constipation score. 
A scale of constipation severity including impact of symptoms on the patient’s life. 
 Scores range from 0 to 30, with higher scores representing more severe symptoms. 
Widely used, validation compared to physiological measures identified.(Agachan et al.,1996). 
CCIS 
Cleveland Clinic Incontinence 
Score. Also known as Wexner 
incontinence score 
The CCI Score takes into account the frequency of incontinence and the extent to which it alters a 
person’s life. . Scores range from 0 to 20, with higher scores representing more severe symptoms. 
Widely used, but no formal validation identified. 
(Jorge et al., 1993) 
FIGS or SMFIGS 
St Mark’s fecal incontinence 
grading system 
A scale of incontinence severity including the impact of symptoms on the patient’s life. 
Scores range from 0-24 with 24 most severe. 
Widely used and validated for use in adults, specific diagnoses not specified (Vaizey et al., 1999). 
NBDS Neurogenic bowel 
dysfunction score 
Ten questions on bowel dysfunction symptoms. Questions do not ask about the impact of symptoms on 
the patient. 
Scores range from 0 – 47, with 47 most severe.  
 Widely used, validated for use in patients 15+ years  with SCI. (Krogh et al., 2006). It has also been 
used in other patient groups. Translated into several languages.  
Available on Coloplast website. 
ASCRS American Society of Colon 
and Rectal Surgeons fecal 
incontinence score 
Symptom related QoL score, with 4 subscales for lifestyle, coping behaviour, depression, 
embarrassment. Each on a scale of 0-4 with 4 most severe. 
No information on validation identified. 
FICQOL Fecal Incontinence/ 
Constipation Quality of Life 
Reports on the impact on quality of life for both children with spina bifida and caregivers. Information on 
bowel care regimen, functional outcomes, 19 scaled questions on impact of incontinence on child’s and 
carer’s lives.  
Validated for children with spina bifida. (Nanigian et al., 2008) 
FIQOL Fecal Incontinence Quality 
of Life 
29 items in 4 QoL scales, including lifestyle, coping/behaviour, depression/self-perception, 
embarrassment. 
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Adults 18+(Rockwood et al., 2000) 
Fecal continence score/ Rintala 
Score 
Score to determine the severity of fecal incontinence in children.  
Scores range from 0-20 with 20 most severe 
Refered to as validated, but original paper does not appear to contain validation (Rintala et al., 1995). 
Developed for use in children who had undergone surgical repair for anorectal anomaly. 
NBDoS Neurogenic bowel 
dysfunction score 
Score to determine the severity of bowel dysfunction in children, and impact on quality of life. 
Score range is not explicitly stated. 15 questions, with varying levels of response for each question (0-
4). EAC calculated possible range of scores to be 0-41, with 41 as worst health. 
Validated for children with spina bifida (Kelly, Hannan et al. 2016) 
CHQ-pf50 Child Health 
Questionnaire Parent Form 
A generic quality of life score, containing 50 items. Proxy administered (by parent) 
Paediatric, 5-18 years. Self-administered youth form also available. 
Score is 0-100, with 100 the best quality of life possible. 
. Widely used, and validated (Landgraf et al .,1999)  
SF-36 Short Form Health Survey-
36 
Generic quality of life score. Self administered or by interview.For use in adults 18+ 
Scores 0-100, with 100 as best health. Very widely used, and validated (McHorney et al,. 1994) 
EQ5D3L EuroQoL-5D Generic quality of life score. With 243 health states descriptive with 5 dimensions, each with 3 levels– 
mobility, self-care, usual activity, pain/discomfort, anxiety/depression. 
Scores are used with a validation set for the appropriate country to give a final value of 0-1 with 1 the 
best possible quality of life. 
Patient reported outcome, self administered or by interview. For use in ages 12+ 
Generic across clinical areas, very widely used and validated. (The EuroQol Group 1990)  
EQ5D-VAS EuroQoL-5D Visual 
Anologue Scale 
Scores 0-100 where 100 is perfect health. Part of the EQ5D questionnaire. 
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Appendix D Costs and resource use as submitted by the company 
Value unit size 
Cost per 
unit 
Resource use Weekly cost per 
patient, where 
applicable Source 
Peristeen      
System 1 £74.78 
1 per 6 months £2.87 Peristeen only NHS Electronic Drug Tariff, June 
2015 
Catheters (15 in pack) 1 £130.33 
1 per month £29.96 Peristeen only NHS Electronic Drug Tariff, June 
2015 
Initial consultation 1 hour £142.00 
1 at start of Peristeen 
use 
n/a 
Consultant visit, PSSRU 2014 
Follow-up phone call 1 hour £100.00 
3 x 15 min at start of 
Peristeen use 
n/a 
Nurse, day ward, PSSRU 2014 
Standard bowel care See note below for explanation of frequency calculation 
Bulking agent: Fybogel 
sachet (3.5g) 30 £2.29 
2.8 sachets per day 
for those using  
£0.88 Peristeen 
£0.14 SBC Fybogel 3.5g sachet, BNF 69 
Softener: docusate 100 £6.98 
430mg per day for 
those using 
£0.71 Peristeen 
£0.65 SBC Dioctyl 100mg, BNF 69 
Stimulant: bisacodyl 100 £3.43 
16mg per day for 
those using 
£0.34 Peristeen 
£0.45 SBC Bisacodyl 5mg tablets, BNF 69 
Osmotic: Movicol (13.7g 
sachet – EAC Comment) 50 £11.13 
2.9 sachets per day 
for those using# 
£3.01 Peristeen 
£0.77 SBC Movicol oral powder, BNF 69 
Suppository glycerine 12 £1.94 
1.4 every other day 
for those using# 
£0.59 Peristeen 
£0.49 SBC Glycerol 4-g mould, BNF 69 
Suppository bisacodyl 12 £1.57 
1.0 every other day 
for those using# 
£0.02 Peristeen 
£0.04 SBC 
Bisacodyl 10mg suppositories, 
BNF 69 
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Enema 1 £0.66 
1.2 every other day 
for those using# 
£0.50 Peristeen 
£0.28 SBC Norgalax 10-g unit, BNF 69 
Anal plug 20 £44.89 
1 per day + 1 per 
episode of faecal 
incontinence for 
those using# 
£7.65 Peristeen 
£10.11 SBC 
NHS Electronic Drug Tariff, June 
2015 
Incontinence pad 7 £5.95 
1 per day + 1 per 
episode of faecal 
incontinence for 
those using# 
£28.30 Peristeen 
£37.49 SBC 
Retail price provided by Coloplast 
      
Off-label      
Lubiprostone 56 £53.48 Not used in model Not used in model Amitiza 24ug,BNF 69 
Prucalopride 28 £59.52 Not used in model Not used in model Resolor 2mg, BNF 69 
      
3rd line treatment Patients going to 3rd line treatment are given a 33% probability of going to either of the three treatments 
SNS initial procedure per episode £9,368.00 Procedure cost n/a NICE 2013, inflated 
SNS follow up 1 hour £6,286.00 
Follow up, description 
not given, occurs 
once in 7 years 
£17.40 
 
NICE 2013, inflated 
SARS initial procedure per episode £7,770.00 
Procedure cost n/a Dagenais 2013 (10,500 EUR 
converted to GBP at 1 EUR=0.74 
GBP and inflated) 
SNS outpatient 
appointment 1 hour £118.92 
Follow up every two 
months 
£13.67 
 
Colorectal surgery outpatient 
attendance, NHS reference costs 
2013-14 
ACE initial procedure per episode £3,870.33 
Procedure cost n/a Major large intestine procedure, 
NHS reference costs 2013-14 
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SNS outpatient 
appointment 1 hour £118.92 
Follow up every two 
months 
£13.67 
 
 
Colorectal surgery outpatient 
attendance, NHS reference costs 
2013-14 
      
Stoma      
Surgery 1 £7,459.76 
Procedure cost n/a Very complex, complex and major 
large intestine procedure, NHS 
reference costs 2013-14 
Colostomy bag 30 £87.00 
two per day £40.60 NHS Electronic Drug Tariff, June 
2015 
Belt 1 £6.78 
one per month £1.56 NHS Electronic Drug Tariff, June 
2015 
Skin barrier 
30 
applications £22.24 
twice per day £10.38 NHS Electronic Drug Tariff, June 
2015 
Adhesive remover 
30 
applications £14.96 
twice per day £6.98 NHS Electronic Drug Tariff, June 
2015 
      
HCP visits      
Consultant 1 hour £142.00 
Peristeen 0.88/year 
SBC: 1.04/year 
Peristeen: £2.40 
SBC: £2.84 PSSRU 2014 
Dietician 
1 hour 
£37.00 
Peristeen 0.19/year 
SBC: 0.57/year 
Peristeen: £0.14 
SBC: £0.40 PSSRU 2014 
GP 
1 hour 
£234.00 
Peristeen 2.89/year 
SBC: 3.75/year 
Peristeen: £12.93 
SBC: £16.81 PSSRU 2014 
      
Time spent on bowel 
management   
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Caregiver salary 1 hour £24.00 
Peristeen: 
19 min/day for 30% 
SBC: 26 
min/day for 44% 
Peristeen: £51.07 
SBC: £74.01 
SHOULD BE: 
Peristeen: £16.17 
SBC: £32.07 
 PSSRU 2014 
AEs      
2nd line      
UTI (responding to initial 
treatment) per episode £167.77 
Peristeen: 0.67/year 
SBC: 1.37/year 
Peristeen: £2.17 
SBC: £4.41 
 Bermingham 201346 
Overall hospitalisation   
Peristeen: 0.28/year 
SBC: 0.63/year 
 
 
Gastrointestinal infection per episode £1,998.84 
20% of 
hospitalisations 
Peristeen: £2.16 
SBC: £4.86 
Gastrointestinal infection, NHS 
reference costs 2013-14 
Pressure ulcer 
management per episode £26,188.26 
20% of 
hospitalisations  
Peristeen: £28.30 
SBC: £63.68 
Grade 4 pressure ulcer, SCNs High 
Impact Action Steering Group 
2010, inflated 
Falls or other trauma per episode £2,326.32 
20% of 
hospitalisations 
Peristeen: £2.51 
SBC: £5.66 
Falls without specific cause, NHS 
reference costs 2013-14 
Abdominal pain per episode £1,432.09 
20% of 
hospitalisations 
Peristeen: £1.55 
SBC: £3.48 
Abdominal pain with and without 
interventions, NHS reference 
costs 2013-14 
UTI per episode £2,485.03 
20% of 
hospitalisations 
Peristeen: £2.69 
SBC: £6.04 
Kidney or Urinary Tract Infections, 
NHS reference costs 2013-14 
      
L/P  £0.00 Not used in model  Assumption 
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3rd line  £212.34 once per two years £2.03 NICE 2013, inflated 
      
Stoma      
Peristomal complications per episode £34.89 
61% of patients,  
Peristeen 7.3/year 
SBC: 1/ year 
Peristeen £3.13 
SBC: 0.42 
Meisner 201247 
Hernia complications per episode £3,355.69 
18% of patients, 
3/year 
£34.71 Hernia procedure, NHS reference 
costs 2013-14 
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Appendix E Additional information submitted by the company 
Following enquiries by the EAC concerning the audit data and its use in the model, the company provided an extract of the audit 
data showing quality of life outcomes and length of Peristeen use. Further queries were made by the EAC concerning calculation of 
transition probabilities, following which the company submitted an amended model based on 150/227 patients stopping Peristeen 
use over 6 years, rather than 117/227 previously modelled.  
The impact of the altered transition probabilities on the length of Peristeen use that was modelled is shown in figure 8.  
The additional model submitted had not been changed to correct the errors identified by the EAC, however when these changes 
were made (errors 1-8, and cost alterations 11 and 12, in table 15) the result was: 
 Peristeen 
Standard 
Bowel Care 
Cost saving 
per patient 
TOTAL £96,157 £99,248 -£3,092 
The EAC felt that the variable transition probabilities used in the EAC base case were more appropriate, and no changes were 
made to the EAC base case or sensitivity analysis. 
 
Figure 8. Effect of different transition probability calculations 
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Appendix F Trials identified at Clinicaltrials.gov  
ID Number Status Title Condition: Intervention Notes 
NCT0178432 Completed Peristeen Bowel 
Irrigation System in 
Cauda Equina 
Cauda Equina 
Syndrome 
Peristeen 
Bowel 
Irrigation 
System 
Single-armed 
study. 
NCT00286520 Completed Treatment of Faecal 
Incontinence and 
Constipation in Patients 
With Spinal Cord Injury 
Constipation, 
Faecal 
incontinence,  
Spinal Cord Injury 
Transanal 
irrigation with 
Peristeen Anal 
Irrigation 
Included in 
submission – 
Christensen 
2006 
NCT01059370 Completed Autonomic Dysreflexia 
in Spinal Cord Injury 
Autonomic 
dysfunction,  
 Spinal cord 
injury 
Bowel 
emptying 
Included in 
submission – 
Faarborg 2014 
NCT01313026 Recruiting Treatment of "Low 
Anterior Resection 
Syndrome" by 
Percutaneous Nerve 
Evaluation and 
Transanal Irrigation 
Rectal Cancer Intervention:
 Proced
ure: 
Percutaneous 
nerve 
evaluation 
Randomised 
crossover trial.  
Estimated 
completion 
date Dec 2019 
 
   94 of 139 
External Assessment Centre report: Peristeen anal irrigation system 
Date: June 2017 
Appendix G Quality appraisals 
Quality appraisal forms are from the following source: Specialist Unit for 
Review Evidence (SURE)Questions to assist with the critical appraisal of 
cohort studies1  
1This work is licensed under the Creative Commons Attribution - Non Commercial-ShareAlike 3.0 Unported 
License. To view a copy of this license visit http://creativecommons.org/licenses/by-nc-sa/3.0/  
Citation:  Chan 2011 
Are there other companion papers from the same study? Don’t know 
 Yes/ Can't tell/ No 
1. Is the study design clearly stated? Somewhat. 
Not described as a cohort study but as a 
prospective data collection. Analysis used 
before-and-after intra-patient comparison. 
Not clear whether analyses were planned a 
priori. 
2. Does the study address a clearly focused question? 
Consider:  Population; Exposure (defined and accurately 
measured?); Comparator/Control; Outcomes. 
Yes. 
P:  patients presenting with chronic 
constipation and/or faecal incontinence (who 
did not respond to conservative management 
and in whom surgery was not indicated) 
E:  Instruction in use of rectal irrigation 
system (may not be Peristeen) 
C: intra-patient before-after comparison 
O: CCCS (constipation) & CCIS 
(incontinence) scores; patient satisfaction; 
adverse effects 
3. Are the setting, locations and relevant dates 
provided? 
Consider: recruitment period; exposure; follow-up & data 
collection. 
Yes. 
Single site, joint functional bowel clinic. 
Attendance 1/6/05-13/8/09. Outcomes 
measured after 6 months at OP review. 
Available for follow-up = 83% constipation 
group; 65% incontinence group. 
4. Were participants fairly selected? 
Consider: eligibility criteria; sources & selection of 
participants; method of follow-up; for matched studies – 
details of matching criteria and number of exposed or 
unexposed. 
Can’t tell. 
Inclusion and exclusion criteria were not 
specifically defined. 
May have been bias in patient selection due 
to subjective inclusion criteria and single 
consultant/nurse decision-making. Some 
patients lost to follow-up. 
5. Are participant characteristics provided? 
Consider if: sufficient details; a baseline table is included. 
Yes. 
Baseline table includes age, sex, and 
predominant symptoms (constipation or 
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faecal incontinence). Main analysis was 
intra-patient comparison so baseline not too 
important. 
6. Are the measures of exposures & outcomes 
appropriate?  
Consider if the methods of assessment are valid & reliable. 
Exposure: No record of timing/frequency of 
(self-administered) treatment. 
Outcomes: CCCS/CCIS are apparently 
validated measures, but are subjective. But 
definitions of “success/improvement” relied 
on arbitrary thresholds. 
7. Was bias considered? e.g. recall or selection bias Somewhat. 
No apparent consideration of selection bias 
or attrition bias. 
Acknowledged small numbers when 
referring to subgroups. 
8. Is there a description of how the study size was 
arrived at? 
No.  
All eligible patients presenting to a single 
clinic over 4 years (n=91). Acknowledged 
small sample size when referring to 
subgroups. 
9. Are the statistical methods well described? 
Consider: How missing data was handled; were potential 
sources of bias (confounding factors) controlled for; How loss 
to follow-up was addressed. 
Possible error in interpretation. 
Authors describe use of non-parametric tests 
(Wilcoxon’s signed ranks), but report mean 
scores (without SD or confidence intervals). 
10. Is information provided on participant flow?  
Consider if following provided: flow diagram; numbers of 
participants at each stage; details of drop-outs; details of 
missing participant data; follow-up time summarised; 
numbers of outcome events. 
Some. 
 271 patients reviewed in clinic. 
 91 eligible for inclusion (60 
constipation; 32 faecal incontinence) 
 70 included in follow-up (50; 20) at six 
months. No details about the 21 patients 
lost to follow-up. 
 37 discontinued treatment (25: 12) – not 
clear after how long. 
11. Are the results well described? 
Consider if: effect sizes, confidence intervals/standard 
deviations provided; the conclusions are the same in the 
abstract and the full text. 
No. 
 Poor reporting of statistical results (no 
SD, median/IQR, confidence intervals). 
 Pre-treatment scores seem to include 
patients for whom post-treatment scores 
were unavailable (n=21; 23%). Unlikely 
to be a fair comparison (patients with 
poorer outcomes are more likely to have 
withdrawn). 
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 Authors claim that this study 
demonstrates that rectal irrigation “is 
effective in managing the symptoms of 
chronic constipation and faecal 
incontinence”, despite more than half of 
patients discontinuing treatment due to 
lack of improvement! 
12. Is any sponsorship/conflict of interest reported? “The authors have no conflicting interests to 
declare” 
13. Finally…Did the authors identify any limitations 
and, if so, are they captured above? 
The only limitation reported by the authors 
was the small subgroup samples precluding 
statistical analysis. 
 
 
Citation:  Christensen 2006 
Study Design: RCT 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary 
outcome? 
Patients with spinal cord injury with 
neurogenic bowel dysfunction 
Transanal irrigation (Peristeen) 
Conservative bowel management (best 
supportive bowel care without irrigation) 
CCCS & St Mark’s fecal incontinence 
grading system scores (composite primary 
outcome). 
2.   Was the population randomised? 
 If YES, were appropriate methods 
used? 
Eg: random number tables, opaque 
envelopes 
Yes 
 
Yes 
Note: The following methods are 
not appropriate: alternating 
participants coin toss, birth dates, 
record numbers, days of the week 
Computer-generated sequence obtained 
from opening a sealed numbered 
envelope. 
3. Was allocation to intervention or 
comparator groups concealed? 
Yes 
Is it possible for those allocating to 
know which group they are 
allocating people to?  
As above, methods such as 
alternating participants coin toss, 
birth dates, record numbers, days of 
the week will not allow appropriate 
allocation concealment. 
“The randomisation sequence could not be 
previewed”. 
4.  Were participants/investigators 
blinded to group allocation? If NO, 
No.  
“Due to the nature of the two interventions, 
any blinding was impossible” 
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was assessment of outcomes 
blinded? 
Outcome data was obtained by “an 
independent observer who had not 
participated in the training of the subject”; 
this person did not appear to have been 
blinded to group allocation. 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were 
the groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Can’t tell 
 
Not clear whether patients using Peristeen 
were also provided with other bowel care 
eg advice regarding diet, fluids and 
physical activity. 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Yes 
“It was approved by the local research 
ethics committees”. 
7. Was a trial protocol published?  
Was a protocol published in a 
journal or clinical trial registry before 
participants were recruited?  
If a protocol is available, are the 
outcomes reported in the paper 
listed in the protocol? 
Can’t tell  
No reference to protocol in this 
manuscript. 
8. Were the groups similar at the start 
of the trial? 
Are baseline characteristics 
provided and discussed (eg age, 
sex, social class, life style etc.)?  
Are any differences >10%? 
Somewhat 
Baseline outcomes were not statistically 
dissimilar. Baseline demographics were 
tabulated without statistical comparisons, 
but there was an “apparent imbalance” of 
mobility (wheelchair use = 29/42 
intervention; 40/45 control). Authors 
reported outcomes separately by mobility 
status, but not in the overall study 
conclusions. Looks like only those 
confined to a wheelchair/bed actually 
benefitted (see table 4).  
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If 
YES, for which outcome? 
Were there sufficient participants? 
Yes 
Power calculation for primary outcome 
(combined outcome of constipation + 
incontinence scores). 
Needed 80 pts (min 10 per centre). n=87 
(ITT); n=81 (PP). 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the 
groups to which they were 
randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long 
enough? 
 
Yes 
Can’t tell. 
“Data were analyzed on an intention-to-
treat basis” “missing data at termination 
were substituted with baseline data from 
the same patient” 
10-week follow-up (last 4 weeks included 
in efficacy analyses; all 10 weeks in safety 
analyses). Patients “were contacted” each 
week during follow-up to complete a short, 
structured questionnaire – not clear how 
contact was made. 
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Citation:  Christensen 2008 
Are there other companion papers from the same study? Yes. Subjects previously 
participated in the Christensen 2006 RCT 
 Yes/ Can't tell/ No 
1. Is the study design clearly stated? Not very clear initially, but was able to 
unpick that this was a intra-patient 
11. Data analysis 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of 
bias (confounding factors) 
controlled for; How loss to follow-up 
was addressed. 
 
Yes 
ITT analysis. Used last observation carried 
forward for missing outcome data. 
 
In their later publication (Christensen 
2008), the authors state that “data from 
the main study were not corrected for 
possible confounders” (referring to the 
finding that immobilised patients showed 
the greatest improvement in faecal 
incontinence). 
12. Results 
Were outcome measures reliable 
(eg objective or subjective 
measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes 
assessed? 
Are the authors' conclusions 
adequately supported by the 
results? 
 
St Mark’s fecal incontinence scoring 
system not validated in spinal cord injury 
patients. 
Some subjective outcomes used (eg 
“patients were asked for their level of 
dependency with actual bowel care”). 
Device problems (eg burst balloons) were 
only reported voluntarily in a “space left for 
comments in the questionnaire” – may be 
underreported? 
Some outcomes (frequency of UTI; use of 
laxatives etc) were only reported in the 
discussion section, without supporting 
data. 
13.  Is any sponsorship/conflict of 
interest reported? 
Study was “Supported by Coloplast A/S” 
(Peristeen manufacturer). No further 
declarations were reported. 
14.  Finally…consider:  
Did the authors identify any 
limitations? 
Are the conclusions the same in the 
abstract and the full text? 
 
Authors refer to potential “information 
bias”, because “many of the patients had 
struggled with bowel dysfunction for years” 
and “were offered an opportunity to try 
transanal irrigation as a novel and 
attractive solution”. 
In the discussion, the authors note that 
“the inclusion criteria used selected 
patients experiencing more severe 
problems with bowel care. However, many 
spinal cord-injured patients achieve 
adequate bowel function with laxatives 
and digital stimulation alone”. 
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before-after study. 
2. Does the study address a clearly 
focused question? 
Consider:  Population; Exposure 
(defined and accurately measured?); 
Comparator/Control; Outcomes. 
Yes 
Patients with spinal cord injury and 
neurogenic bowel dysfunction 
Transanal irrigation (Peristeen) 
Intra-patient comparison with 
conservative bowel management  
Change in bowel function (CCCS, FIGS 
& NBD); factors predicting outcome 
Primary outcome is not specified 
3. Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; 
exposure; follow-up & data collection. 
Yes 
Patients recruited from 5 spinal cord 
injury centres in 5 European countries 
(listed in Table 1). 
42 patients underwent transanal 
irrigation for 10 weeks as part of the 
(previously reported) RCT, with 
recruitment between Dec 2003 & June 
2005. 20 additional patients underwent 
transanal irrigation for a 10 week 
extension period, after having received 
conservative bowel management as 
participants in the control group in the 
RCT. 
Patients “were contacted” each week 
during follow-up to complete a short, 
structured questionnaire – not clear how 
contact was made. 
4. Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – 
details of matching criteria and 
number of exposed or unexposed. 
Yes 
Patients were originally recruited to the 
Christensen RCT (note that only patients 
experiencing severe problems were 
eligible to participate in the trial). 
20 of 62 patients had received best 
supportive care for 10 weeks under trial 
conditions prior to initiation of rectal 
irrigation treatment. 
5. Are participant characteristics 
provided?Consider if: sufficient 
details; a baseline table is included. 
Yes 
See table 1. 
6. Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of 
assessment are valid & reliable. 
St Mark’s fecal incontinence scoring 
system not validated in spinal cord injury 
patients. 
Some subjective outcomes used (eg 
“patients were asked for their level of 
dependency with actual bowel care”). 
7. Was bias considered? e.g. recall or 
selection bias 
May be selection bias. Not clear why 
only 20 of the 45 patients in the trial 
control arm were offered transanal 
irrigation in the extension period. 
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8. Is there a description of how the study 
size was arrived at? 
No, not for this intra-patient extension. 
The authors refer to the power 
calculation from the prior RCT 
(Christensen 2006) and admit that this 
“study was not powered to support the 
multivariate analyses presented in this 
paper”. 
9. Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of 
bias (confounding factors) controlled 
for; How loss to follow-up was 
addressed. 
Yes 
Intra-patient comparison reduces some 
confounders. Outcomes may be affected 
by changes in practice over time (though 
unlikely within a 10 week period).  
 “Data were analysed on an intention-to-
treat basis”. Used last-observation-
carried-forward. 
It is a limitation that the design did not 
include a crossover (from intervention to 
control), which could have improved 
reliability of the results. 
10. Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at 
each stage; details of drop-outs; 
details of missing participant data; 
follow-up time summarised; numbers 
of outcome events. 
Yes 
Details of numbers and reasons for 
patient withdrawals were provided. 
11. Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations 
provided; the conclusions are the 
same in the abstract and the full text. 
There appears to be some contradictory 
reporting relating to the influence of 
uncontrolled anal spasms on treatment 
benefit, however this is not a primary 
study outcome. 
Outcomes differed significantly between 
study centres, suggesting that there 
were additional confounders which had 
not been accounted for. The authors do 
not provide an explanation, except to 
note that “the lead center, which had the 
most experience in transanal irrigation, 
had results in the middle of the range, 
indicating that the concept of transanal 
irrigation is transferable to other settings 
and cultures”. 
12. Is any sponsorship/conflict of interest 
reported? 
Study was “Supported by Coloplast A/S” 
(Peristeen manufacturer). No further 
declarations were reported. 
13. Finally…Did the authors identify any 
limitations and, if so, are they 
captured above? 
This study found that patients who were 
mobile were more likely to benefit than 
those who were immobile. This 
contradicts findings from the main RCT 
(Christensen 2006). The authors 
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attribute this to the fact that “data from 
the main study were not corrected for 
possible confounders”. 
 
Citation:  Del Popolo 2008 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
1. Is the study design clearly stated? Multicentre before-and-after study. 
2. Does the study address a clearly 
focused question? 
Consider:  Population; Exposure 
(defined and accurately measured?); 
Comparator/Control; Outcomes. 
P: People with severe neurogenic bowel 
dysfunctions (NBD) with unsatisfactory 
bowel management 
I: Self-administered Transanal irrigation 
(Peristeen) 
C: Intra-patient baseline data 
O: NBD symptoms, QoL. No primary 
outcome measure specified. 
3. Are the setting, locations and 
relevant dates provided? 
Consider: recruitment period; 
exposure; follow-up & data collection. 
Questionnaire was “hospital administered 
during initial and control visits” by medical 
personnel. Not clear how data were 
collected at follow-up (3 weeks). 
4. Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – 
details of matching criteria and 
number of exposed or unexposed. 
No specific concerns. 
5. Are participant characteristics 
provided? 
Consider if: sufficient details; a 
baseline table is included. 
Age/sex reported in main text, other 
baseline characteristics were reported in 
table 1. 
6. Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of 
assessment are valid & reliable. 
The questionnaire was not validated for 
use in Italian. 
Many of the outcome measures were 
subjective. 
7. Was bias considered? e.g. recall or 
selection bias 
No 
8. Is there a description of how the 
study size was arrived at? 
No (n=36). 
9. Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of 
bias (confounding factors) controlled 
for; How loss to follow-up was 
addressed. 
The McNemar test was used to analyze 
the ordinal variables and for the before-
and-after comparison of dichotomous 
variables; the Sign test was used for 
numerical scale variables or value 
variables (likert scales) and variation for 
numerical scales (from 0 to 10).  
Handling of confounders was not 
addressed, except that “Patients using 
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Citation:  Grainger Pre-publicaton 
Are there other companion papers from the same study? 
 ******************* 
1. Is the study design clearly stated? ************************************
************************************
******** 
2. Does the study address a clearly 
focused question? 
Consider:  Population; Exposure (defined 
and accurately measured?); 
Comparator/Control; Outcomes. 
************************************
************************************
************************************
************************************
************************** 
3. Are the setting, locations and 
relevant dates provided? 
Consider: recruitment period; exposure; 
follow-up & data collection. 
************************************
************************************
************************ 
drugs or alternative methods for 
evacuation discontinued their treatment 7 
days before entering the study”. Could this 
have impacted adversely on baseline 
QoL? 
This was an intra-patient comparison and 
therefore some potential confounders 
would not be relevant. 
10. Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at 
each stage; details of drop-outs; 
details of missing participant data; 
follow-up time summarised; numbers 
of outcome events. 
One patient was lost to follow-up (no 
reason given) and “was accounted for in 
the analysis using statistical methods” (not 
specified). 
11. Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations 
provided; the conclusions are the 
same in the abstract and the full text. 
Numbers of patients giving different 
responses are presented in tables 3-5; 
these were reported to be statistically 
significant (p≤0.001) but without much 
further detail. Median before/after scores 
might have been helpful? 
Some outcomes were reported only as 
descriptive statistics (eg change in level of 
dependency). 
12. Is any sponsorship/conflict of interest 
reported? 
This research was supported for data 
analysis by Coloplast Italia. 
13. Finally…Did the authors identify any 
limitations and, if so, are they 
captured above? 
They acknowledge that “only a small 
number of patients participated in this brief 
study” and that longer-term follow-up 
would be of benefit. 
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4. Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of follow-
up; for matched studies – details of matching 
criteria and number of exposed or 
unexposed. 
************************************
************************************
************************************
************************************
************************************
************************************
************************************
************************************
************************* 
5. Are participant characteristics 
provided? 
Consider if: sufficient details; a baseline 
table is included. 
************************************
************************************
************************************
************************************
************************************
************************************ 
6. Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment are 
valid & reliable. 
************************************
************************************
************************************
************************************
************************************
************************************
************************************
************************************
** 
7. Was bias considered? e.g. recall or 
selection bias 
************************************
************************************
***************************** 
8. Is there a description of how the 
study size was arrived at? 
*** 
9. Are the statistical methods well 
described? 
Consider: How missing data was handled; 
were potential sources of bias (confounding 
factors) controlled for; How loss to follow-
up was addressed. 
***************** 
10. Is information provided on 
participant flow?  
Consider if following provided: flow 
diagram; numbers of participants at each 
stage; details of drop-outs; details of missing 
participant data; follow-up time summarised; 
numbers of outcome events. 
************************************
****************************** 
11. Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; the 
conclusions are the same in the abstract and 
the full text. 
************************************
************************************
************************************
************************************ 
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12. Is any sponsorship/conflict of interest 
reported? 
** 
13. Finally…Did the authors identify any 
limitations and, if so, are they 
captured above? 
************************************
****************** 
 
Citation:  Hamonet-Torny 2013 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? Yes. Retrospective cohort study. 
Does the study address a clearly 
focused question? 
Consider:  Population; Exposure 
(defined and accurately measured?); 
Comparator/Control; Outcomes. 
No. “the main objective was to determine 
the long-term outcome of transanal 
irrigation with Peristeen and its predictive 
factors” 
P: The first patients treated with Peristeen 
at a single site (for constipation or faecal 
incontinence) 
I: Transanal irrigiation using Peristeen 
(continued use at follow-up, of varying 
length) 
C: Patients who had discontinued use of 
Peristeen at follow-up (varying length) 
O:Time to discontinuation of Peristeen 
treatment, reasons for discontinuation, 
adverse effects, consumption of laxatives, 
patient satisfaction 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; 
exposure; follow-up & data collection. 
Location/setting – yes. Treatment was 
initiated at a single hospital site. Use after 
discharge differed as some patients were 
assisted by a nurse and/or family member 
(at home or in an “institution”), whilst others 
self-administered treatment. 
Dates – no: “All patients...since 2010” 
Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – details 
of matching criteria and number of 
exposed or unexposed. 
No. Simply selected “the first 16 patients 
treated by Peristeen” [sic] 
Laxative use was compared for patients 
who had continued use of Peristeen (n=10), 
with those who had discontinued use (n=6), 
for varying lengths of follow-up (overall 
mean 31 months; SD 18 months; range 
7.5-66 months). 
Are participant characteristics 
provided? 
Consider if: sufficient details; a 
Yes. Basic details (age, sex, symptoms, 
underlying pathology) – see table 1. 
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baseline table is included. 
Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment 
are valid & reliable. 
No. There was very little control or 
consistency throughout this study. 
Was bias considered? e.g. recall or 
selection bias 
No. Strong likelihood of selection bias. 
Is there a description of how the study 
size was arrived at? 
Only that they included “the first patients” 
who were treated with Peristeen. No 
sample size calculation, and definitely 
underpowered. 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of 
bias (confounding factors) controlled 
for; How loss to follow-up was 
addressed. 
No. Very poor. Only “Quantitative variables 
were compared using t test of Student and 
qualitative variables with Fisher test” [sic]. 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at 
each stage; details of drop-outs; 
details of missing participant data; 
follow-up time summarised; numbers 
of outcome events. 
Some details provided, but the small 
sample size and variation in lengths of 
follow-up are important limitations. 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the conclusions are the same in the 
abstract and the full text. 
‘Efficacy’ results (use of laxatives, NBD, 
CCS) very poorly designed and so would 
not consider evidence to be robust. 
May be of use for information about 
adverse effects. 
Is any sponsorship/conflict of interest 
reported? 
“The authors declare that they have no 
conflicts of interest”. 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Yes. “Due to the small size of our sample 
and missing data related to its retrospective 
nature, our study suffers from a lack of 
power”. 
 
 
Citation:  Kim 2013 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
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Is the study design clearly stated? No, described as “a 6-month follow-up 
study”. Actually a prospective cohort 
study. 
Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined 
and accurately measured?); 
Comparator/Control; Outcomes. 
Yes 
“The aim of this study was to 
investigate the outcomes of transanal 
irrigation use by spinal cord injury 
patients in (South) Korea with the 
objective of identifying factors 
significantly related to patient-reported 
success”. 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; exposure; 
follow-up & data collection. 
Yes 
Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – details of 
matching criteria and number of exposed 
or unexposed. 
Yes - no particular concerns. 
Authors provided statistical information 
about the differences and similarities 
between the compliant and non-
compliant group. 
Are participant characteristics provided? 
 
 
 
Consider if: sufficient details; a baseline 
table is included. 
Yes. Demographic (table 1) and 
baseline data (table 2) were provided 
for the whole cohort. Demographic and 
baseline characteristics were 
compared between compliant and non-
compliant groups (table 3).  
Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment 
are valid & reliable. 
Outcome data was collected by 
questionnaire. There was no evidence 
that this was a validated tool. 
Was bias considered? e.g. recall or 
selection bias 
Baseline characteristics of compliant 
and non-compliant patients were 
compared (presumably to account for 
any bias). The non-compliant group 
were those who more often needed 
assistance. 
Is there a description of how the study 
size was arrived at? 
No 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
Fairly well described. However there 
was a large number of patients who 
discontinued treatment, and whose 
data were not included in the before-
after comparison. 
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loss to follow-up was addressed. 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at each 
stage; details of drop-outs; details of 
missing participant data; follow-up time 
summarised; numbers of outcome 
events. 
Yes – flow diagram with reasons for 
withdrawals at 1,3, and 6 months. 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the conclusions are the same in the 
abstract and the full text. 
Differences between baseline and final 
measures were only analysed for 
those patients who continued use of 
the system for 6 months (18/52, 34%). 
An ITT analysis is likely to have 
generated more accurate, and 
different, results. 
Is any sponsorship/conflict of interest 
reported? 
“This study was partly supported by 
Coloplast Korea”. 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
No. 
Citation:  Loftus 2012 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? “Observational study” 
Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined 
and accurately measured?); 
Comparator/Control; Outcomes. 
P: Patient with a SCI or spina bifida 
and NBD who had failed conservative 
bowel management. 
I: Transanal irrigation (Peristeen) 
C: Before-after comparison 
O: CCCSS, SMFIGS, NBDS 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; exposure; 
follow-up & data collection. 
Yes. Single site, July 2007-Dec 2009. 
NB: Two (of 11) patients 
retrospectively completed their 
baseline questionnaires as they had 
already started treatment. 
Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – details of 
matching criteria and number of exposed 
Lengths of follow-up varied (3-28 
months) 
Intrapatient comparison.  
All were permitted to use laxatives as 
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or unexposed. required, and had access to telephone 
advice. 
Are participant characteristics provided? 
 
 
 
Consider if: sufficient details; a baseline 
table is included. 
Basic details.  
Age, date of onset, and nature of NBD 
(incomplete/complete SCI & level, or 
spina bifida) were reported individually 
for each pt. Also reported total 
numbers of M/F. 
Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment 
are valid & reliable. 
Used CCCSS, SMFIGS (not validated 
for use in these patients), & NBDS. 
One patient underwent surgery 
(urostomy) during the study period; 
Peristeen was stopped temporarily and 
then restarted (no associated 
timescales reported). 
Was bias considered? e.g. recall or 
selection bias 
Not specifically. 
Is there a description of how the study 
size was arrived at? 
No. Small sample (n=11) 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
Tests were fairly well described. 
No reference to missing data or control 
of confounders. No subgroup analyses 
reported. 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at each 
stage; details of drop-outs; details of 
missing participant data; follow-up time 
summarised; numbers of outcome 
events. 
More detail about actual lengths of 
follow-up (distributions) would be 
useful. We only know that the range 
was 3-28 months, and that 8 (of 11) 
patients were followed up between 3-9 
months. 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the conclusions are the same in the 
abstract and the full text. 
Confidence intervals not reported for 
the main analyses, but mean, SD and 
p-values were. It appears that 
secondary outcomes were only 
reported where there were significant 
differences. 
Some AEs reported. Referred to “burst 
balloons” but not how many (although 
gave another reference which may 
provide more detail about that). 
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Citation:  Nafees 2016 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? Discrete choice experiment 
Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined 
and accurately measured?); 
Comparator/Control; Outcomes. 
P: Patients with NBD (related to SCI, 
MS or spina bifida) 
I: Transanal irrigation 
C: Standard care 
O: Patient preferences and willingness 
to pay for identified attributes. 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; exposure; 
follow-up & data collection. 
A range of data collection dates would 
have been helpful but was not 
reported. 
Similarly a breakdown of geographical 
location (within the UK) may have 
been informative. 
Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – details of 
matching criteria and number of exposed 
or unexposed. 
“Participants were recruited from a 
panel that included people who had 
used Coloplast products at some 
stage, which could result in possible 
bias in their experience of Peristeen 
devices”. 
The study relied upon patients 
completing a survey online, which 
required internet access. This was 
noted by the authors as a possible 
limitation.  
“Efforts were made to recruit a 
representative sample across the UK, 
including consideration of social 
stratum”. 
Are participant characteristics provided? 
Consider if: sufficient details; a baseline 
table is included. 
Yes, demographic (table 2) and clinical 
(table 3) profiles are provided, as well 
as details of current care (table 4). 
Is any sponsorship/conflict of interest 
reported? 
No, not reported. 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Yes – varying lengths of follow-up, and 
the retrospective completion of 
baseline data for 2 patients, as 
mentioned earlier. The authors also 
suggest that longer-term outcomes 
would be helpful. 
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Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment 
are valid & reliable. 
N/A. DCE methods used. 
EQ-5D-5L, St Mark’s FI score and 
CCCSS were reported in the baseline 
table (table 2). 
A consistency check was incorporated 
into the survey. 
Was bias considered? e.g. recall or 
selection bias 
Yes. See no. 4. 
Is there a description of how the study 
size was arrived at? 
No. n=129. The authors report “The 
sample size is relatively limited” and 
“the sample is too small for reliably 
exploring differences between the 
three neurological diseases” (they 
recommended that the subgroup 
analyses be treated as exploratory). 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
N/A. DCE methods used. Attributes 
and levels were combined into choice 
sets using a published orthogonal 
array. An orthogonal fractional factorial 
design was used to identify the 
minimum specification and the 
combinations were paired using a fold-
over design. Data were analysed using 
the conditional logit model. 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at each 
stage; details of drop-outs; details of 
missing participant data; follow-up time 
summarised; numbers of outcome 
events. 
N/A. DCE methods used. 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the conclusions are the same in the 
abstract and the full text. 
Results are well-described and 
explained. Odds ratios not reported in 
the abstract but are fully reported in 
the full text. Confidence intervals and 
willingness to pay are fully and clearly 
reported in the full text. 
Is any sponsorship/conflict of interest 
reported? 
Yes. “This study was supported by 
research funding from Coloplast A/S to 
ICON plc. However no restrictions 
were placed on the design of the 
study, the choice of included data 
sources, the presentation of results, or 
the content of the final manuscript”. 
One author had participated in 
advisory boards for Coloplast and 
other Peristeen manufacturers. Three 
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authors “have conducted this study on 
behalf of Coloplast”. “The authors 
report no other conflicts of interest in 
this work”. 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Yes – mostly captured above (sample 
size, selection bias). The authors also 
noted that the estimates of “willingness 
to pay” may have been biased. Their 
reasoning was that in the UK treatment 
is usually free at the point of delivery, 
so “patients do not have experience of 
making such purchases”. 
 
Citation:  Passananti 2016 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? Not immediately obvious, but appears 
to be prospectively collected data used 
in a before-after study. Also some 
retrospective cohort aspects. 
Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined 
and accurately measured?); 
Comparator/Control; Outcomes. 
P: Adults with multiple sclerosis and 
NBD (which had not responded 
adequately to lifestyle or optimal 
laxative therapy). 
I: Transanal irrigation (Peristeen) 
C: Before-after intrapatient 
comparator. Also retrospectively 
compared those who had discontinued 
treatment (interrupted therapy, n=22) 
with those who had not. 
O: NBDS, EQ-5D (VAS), resource 
utilisation, predictive factors 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; exposure; 
follow-up & data collection. 
Two hospitals in London. 
July 2008-July 2013. 
Minimum 1 year follow-up; mean 40 
months. Kaplan-Meier plot used to 
illustrate lengths of follow-up. 
Were participants fairly selected? 
Consider: eligibility criteria; sources & 
selection of participants; method of 
follow-up; for matched studies – details of 
matching criteria and number of exposed 
or unexposed. 
Yes. Consecutive recruitment of 
eligible patients. 
Are participant characteristics provided? Yes. Not tabulated, but narrative 
description provided for key 
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Consider if: sufficient details; a baseline 
table is included. 
demographics and baseline measures. 
Are the measures of exposures & 
outcomes appropriate?  
Consider if the methods of assessment 
are valid & reliable. 
Generally, yes. Published protocol 
available. 
“All patients were trained to use TAI in 
a standardized manner by the same 
clinical nurse specialist”. “Adjustments 
to the regime of irrigation were made 
by the trainer and patient according to 
a standardized protocol”. 
The authors indicate that there was an 
alteration in the balloon and catheter 
design in 2011. 
EQ-5D & NBDS both validated tools. 
Authors note that the generic EQ-5D 
may not have been sensitive enough 
for this study. 
Was bias considered? e.g. recall or 
selection bias 
“All assessments were collected 
independent of the trainer to minimize 
bias”. 
Resource utilization data were based 
on patient recall, but were validated 
using electronic patient records. 
Is there a description of how the study 
size was arrived at? 
No. n=49. The authors acknowledge 
that this is a ‘modest’ sample size. No 
indication of whether the study had 
sufficient power. 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
Generally yes. Not sure why an 
unpaired t-test was used, with this 
being an intrapatient comparison. 
Perhaps for comparing those who 
discontinued treatment against those 
who did not? 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at each 
stage; details of drop-outs; details of 
missing participant data; follow-up time 
summarised; numbers of outcome 
events. 
Missing data for anorectal physiology 
for 1/49 (2%) patients. 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the conclusions are the same in the 
Yes. 
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abstract and the full text. 
Is any sponsorship/conflict of interest 
reported? 
“No funding declared” and “No 
competing interests declared”. 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Yes: 
No control group 
‘Modest’ sample size 
Absence of stratification for different 
subtypes of MS (to avoid reducing the 
power even further). 
 
Citation:  Preziosi 2012 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
MS patients with NBD 
Persisteen 
Before and after 
Primary -Wexner Constipation 
Incontinence scores 
Secondary – SF-36 health survey 
2.   Was the population randomised? 
 If YES, were appropriate methods 
used? 
Eg: random number tables, opaque 
envelopes 
N/A 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days of 
the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
N/A 
Is it possible for those allocating to know 
which group they are allocating people 
to?  
As above, methods such as alternating 
participants coin toss, birth dates, record 
numbers, days of the week will not allow 
appropriate allocation concealment. 
 
4.  Were participants/investigators 
blinded to group allocation? If NO, was 
N/A 
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assessment of outcomes blinded? 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Good description, no details of other 
treatments used by patients so 
assume none 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Yes 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
Not reported 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided and 
discussed (eg age, sex, social class, life 
style etc.)?  
Are any differences >10%? 
N/A 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Single centre specialised unit so small 
sample to recruit from 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Yes, those who discontinued before 
end of trail were included as ‘intention 
to treat’.  
 
6  month follow-up with interview for 
those still using Peristeen. No data for 
those not using. 
11. Data analysis 
Are the statistical methods well 
described? 
No description how ITT data derived. 
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Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Not a validated score for Wexner 
Consitipation and Incontinence in MS 
patients, subjective score 
 
SF-36 might not be suitable for MS 
patients 
13.  Is any sponsorship/conflict of 
interest reported? 
Funding received from MS Society of 
Great Britain 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
Small sample, no control group 
 
Citation:  Rosen 2011 
Study Design:  uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Patients with low anterior resection 
syndrome 
Persisteen 
Before and after 
Bowel function & QoL 
2.   Was the population randomised? 
 If YES, were appropriate methods 
used? 
Eg: random number tables, opaque 
envelopes 
N/A 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days of 
the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
N/A 
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Is it possible for those allocating to know 
which group they are allocating people 
to?  
As above, methods such as alternating 
participants coin toss, birth dates, record 
numbers, days of the week will not allow 
appropriate allocation concealment. 
 
4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
N/A 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Good description no details if other 
treatments used as well. 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Not reported 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided and 
discussed (eg age, sex, social class, life 
style etc.)?  
Are any differences >10%? 
N/A 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
2 centre study, specialised group so 
small sample to recruit from(n=14) 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
All 14 patients followed-up, all patients 
followed-up for at least 15 months 
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Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
11. Data analysis 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
Adequate 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Subjective measures but unavoidable, 
QoL questionnaires not validated for 
this group of patients 
13.  Is any sponsorship/conflict of 
interest reported? 
Not reported 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
Conclusions match 
 
Small sample (n=14) but specialised 
group, subjective measures but 
unavoidable though not validated for 
sample 
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Citation:  Whitehouse 2010 
Study Design:  uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Patients with FBD 
Persisteen 
None (before and after) 
patient symptom linear analogue 
score (PLAS), faecal incontinence 
grading system and a review sheet 
used to collect functional outcomes – 
not stated if validated 
2.   Was the population randomised? 
 If YES, were appropriate methods 
used? 
Eg: random number tables, opaque 
envelopes 
N/A 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days of 
the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
N/A 
Is it possible for those allocating to know 
which group they are allocating people 
to?  
As above, methods such as alternating 
participants coin toss, birth dates, record 
numbers, days of the week will not allow 
appropriate allocation concealment. 
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4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
N/A 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Reasonable description but limited 
details on laxative use or 
compensatory medicine 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Not reported  
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
Not reported 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided and 
discussed (eg age, sex, social class, life 
style etc.)?  
Are any differences >10%? 
N/A 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Reasonable sample size but no 
power calculation 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Mean length of follow-provided  42 
months 
(7–84) 
 
ITT not used, 39/152 were not 
evaluated (25%) 
11. Data analysis 
Are the statistical methods well 
Reasonable 
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described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; How 
loss to follow-up was addressed. 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Not stated if questionnaire used to 
evaluate functional outcomes was 
validated. 
 
Conclusions match  
13.  Is any sponsorship/conflict of 
interest reported? 
Not reported 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
Reasonable follow-up 
ITT not used  
25% not evaluated 
 
Studies of children 
 
Citation:  Alenezi H et al. 2014 Peristeen anal irrigation 
Are there other companion papers from the same study? NO 
 Yes/ Can't tell/ No 
Is the study design clearly stated? 
Consider if retrospective or prospective 
No – just states prospectively 
evaluated, no comparison group 
Does the study address a clearly 
focused question? 
Consider: population and outcomes (are 
these appropriate?) 
Yes  
Population: children with neuropathic 
bladder & bowel dysfunction 
Outcomes: response to Peristeen as 
measured by complete dryness and 
minimal or constipation, frequency of 
use, satisfaction, diaper independency 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; follow-up 
& data collection. 
Recruitment period: April 2006 to 
present 
Follow up 7 – 89months 
 
Are there explicit inclusion/exclusion Brief – patients intended for 
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criteria? reconstructive bladder surgery 
Were patients enrolled consecutively? Not clear 
Are participant characteristics provided? 
Consider if: sufficient details; a baseline 
table is included. 
Limited detail – age and gender; no 
table 
Are outcome measures appropriate?  
Consider if: the methods of assessment 
are valid & reliable. 
yes 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) 
considered/controlled for. 
No detail 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at 
each stage; details of drop-outs; details 
of missing participant data; follow-up 
time summarised; numbers of outcome 
events. 
Brief details but all patients included 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the results support the conclusions and 
are they the same in the abstract and 
the full text. 
Brief details; number and percentage 
only 
Is any sponsorship/conflict of interest 
reported? 
None  
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Small sample 
Single centre 
 
Citation:  Ausili 2010 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
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Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with myelomeningocele 
Persisteen 
No control, Before and after 
Neurogenic bowel score 
2.   Was the population 
randomised? 
 If YES, were appropriate 
methods used? 
Eg: random number tables, opaque 
envelopes 
Not applicable 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days 
of the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
Not applicable 
Is it possible for those allocating to 
know which group they are allocating 
people to?  
As above, methods such as alternating 
participants coin toss, birth dates, 
record numbers, days of the week will 
not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
Not applicable 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Basic information about intervention, 
no information regarding if other 
treatments used 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Not stated 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
Not stated 
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were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided 
and discussed (eg age, sex, social 
class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Small sample no information on 
potential number of participants, no 
sample size calculation 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Data for all participants 
Follow-up only 3 months 
11. Data analysis 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; 
How loss to follow-up was addressed. 
reasonable 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Element of subjectivity to answers 
13.  Is any sponsorship/conflict of 
interest reported? 
Yes - none 
14.  Finally…consider:  Small sample, lack of control group, 
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Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
short follow-up 
 
Citation:  Corbett P 2014 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with faecal incontinence 
Peristeen 
None, before and after 
Range of functional outcomes 
2.   Was the population 
randomised? 
 If YES, were appropriate 
methods used? 
Eg: random number tables, opaque 
envelopes 
Not applicable 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days 
of the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
Not applicable 
Is it possible for those allocating to 
know which group they are allocating 
people to?  
As above, methods such as alternating 
participants coin toss, birth dates, 
record numbers, days of the week will 
not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
Not applicable 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
Basic information about intervention, 
no information regarding if other 
treatments used 
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comparison adequate? 
Was contamination acceptably low? 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Yes, reported 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
Not stated 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided 
and discussed (eg age, sex, social 
class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Small sample no information on 
potential number of participants, no 
sample size calculation 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Data for all participants 
11. Data analysis 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; 
How loss to follow-up was addressed. 
Basic analysis, Reported as 
median/range 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Reported as median/range. Consistent 
reporting 
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Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
13.  Is any sponsorship/conflict of 
interest reported? 
Yes - none 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
Recall bias of questionnaire 
 
Citation:  Kelly 2016 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with NGB secondary to spina 
bifida 
Persisteen 
No control 
Range of functional scores 
2.   Was the population 
randomised? 
 If YES, were appropriate 
methods used? 
Eg: random number tables, opaque 
envelopes 
Not applicable 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days 
of the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
Not applicable 
Is it possible for those allocating to 
know which group they are allocating 
people to?  
As above, methods such as alternating 
participants coin toss, birth dates, 
record numbers, days of the week will 
not allow appropriate allocation 
concealment. 
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4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
Not applicable 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Basic details of intervention, possible 
compliance issue 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Not stated 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
Not stated 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided 
and discussed (eg age, sex, social 
class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Small sample no information on 
potential number of participants, no 
sample size calculation 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Not all patients were available for full 
follow-up 
 
Follow-up for 6 months but only for 
10/24 
11. Data analysis 
Are the statistical methods well 
reasonable 
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described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; 
How loss to follow-up was addressed. 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Validated questionnaire used but 
possible recall bias as subjective. 
Possible range of scores in 
questionnaire not stated. 
13.  Is any sponsorship/conflict of 
interest reported? 
Not reported 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
Longer follow-up would be beneficial 
 
Citation:  King 2016 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? 
Consider if retrospective or prospective 
Not clear, but non-comparative 
prospective follow-up 
Does the study address a clearly 
focused question? 
Consider: population and outcomes (are 
these appropriate?) 
Children with faecal incontinence  
QoL and functional outcomes 
Are the setting, locations and relevant 
dates provided? 
Consider: recruitment period; follow-up 
& data collection. 
Yes, single centre 
Are there explicit inclusion/exclusion 
criteria? 
No, not clear if all potential patients 
could’ve been included 
Were patients enrolled consecutively? Not clear 
Are participant characteristics provided? 
 
 
Table provided but displayed as users 
and non-users 
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Consider if: sufficient details; a baseline 
table is included. 
Are outcome measures appropriate?  
Consider if: the methods of assessment 
are valid & reliable. 
Reasonable, validated scores used,  
but potential for subjective bias 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) 
considered/controlled for. 
Reasonable 
Is information provided on participant 
flow?  
Consider if following provided: flow 
diagram; numbers of participants at 
each stage; details of drop-outs; details 
of missing participant data; follow-up 
time summarised; numbers of outcome 
events. 
Only 20/33 able to be contacted. Good 
information provided 
Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; 
the results support the conclusions and 
are they the same in the abstract and 
the full text. 
Yes 
Is any sponsorship/conflict of interest 
reported? 
None reported 
Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Small sample, possible issue with 
compliance 
 
Citation:  Koppen 2017 
Are there other companion papers from the same study?No 
 Yes/ Can't tell/ No 
1. Is the study design clearly stated? Yes 
2. Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined and 
accurately measured?); Outcomes. 
Yes 
3. Are the setting, locations and relevant 
dates provided? 
Yes 
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Consider: recruitment period; exposure; data 
collection. 
4. Were participants fairly selected? 
Consider: eligibility criteria; sources & selection of 
participants. 
Convenience sample from one 
clinic, specialised group so difficult.  
5. Are participant characteristics provided? 
Consider if: sufficient details; a table is included. 
Yes 
6. Are the measures of exposures & outcomes 
appropriate?  
Consider if the methods of assessment are valid & 
reliable. 
Outcomes self-report but not with 
validated questionnaire. 
7. Is there a description of how the study size 
was arrived at?  
No as convenience sample 
8. Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
considered/controlled for. 
Reasonable  
9. Is information provided on participant 
flow?  
Consider if following provided: flow diagram; 
numbers of participants at each stage; details of 
drop-outs; details of missing participant data; 
numbers of outcome events. 
Only 74% (67/91) responded, no 
information on those who didn’t 
respond, possible that stopped using 
Peristeen. 27% (18/67) had stopped 
using Peristeen. 
10. Are the results well described? 
Consider if: effect sizes, confidence 
intervals/standard deviations provided; the 
conclusions are the same in the abstract and the full 
text. 
Yes 
11. Is any sponsorship/conflict of interest 
reported? 
Yes, none 
12. Finally…Did the authors identify any 
limitations and, if so, are they captured 
above? 
Children often used other 
medication but unlikely that this 
alone accounted for results. 
 
 
Citation:  Lopez Periera 2009 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly 
focused question/hypothesis 
Yes/Can't tell/No 
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Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with NBD secondary to spina 
bifida 
Persitseen 
No control 
Bowel function and QoL 
 
2.   Was the population 
randomised? 
 If YES, were appropriate 
methods used? 
Eg: random number tables, opaque 
envelopes 
Not applicable 
Note: The following methods are not 
appropriate: alternating participants coin 
toss, birth dates, record numbers, days 
of the week 
 
3. Was allocation to intervention or 
comparator groups concealed? 
Not applicable 
Is it possible for those allocating to 
know which group they are allocating 
people to?  
As above, methods such as alternating 
participants coin toss, birth dates, 
record numbers, days of the week will 
not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators 
blinded to group allocation? If NO, was 
assessment of outcomes blinded? 
Not applicable 
5. Were interventions (and 
comparisons) well described and 
appropriate? 
Aside from the intervention, were the 
groups treated equally? 
Was exposure to intervention and 
comparison adequate? 
Was contamination acceptably low? 
Well described, no details if other 
methods also used 
6. Was ethical approval sought and 
received? 
Do the authors report this? 
Not reported 
7. Was a trial protocol published?  
Was a protocol published in a journal or 
clinical trial registry before participants 
Not reported 
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were recruited?  
If a protocol is available, are the 
outcomes reported in the paper listed in 
the protocol? 
8. Were the groups similar at the 
start of the trial? 
Are baseline characteristics provided 
and discussed (eg age, sex, social 
class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, 
for which outcome? 
Were there sufficient participants? 
Small sample (n=35), not clear if all 
possible participants included 
10. Were participants properly 
accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to 
which they were randomised?  
Was an Intention to Treat analysis 
conducted? 
Was the follow-up period long enough? 
Follow-up reasonable length (mean 
12months) 
11. Data analysis 
Are the statistical methods well 
described? 
Consider: How missing data was 
handled; were potential sources of bias 
(confounding factors) controlled for; 
How loss to follow-up was addressed. 
Reasonable details 
12. Results 
Were outcome measures reliable (eg 
objective or subjective measures)?  
Were all outcome measurements 
complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately 
supported by the results? 
Reasonable detail and consistent 
reporting, questionnaire has potential 
for recall bias 
13.  Is any sponsorship/conflict of 
interest reported? 
Yes, none 
14.  Finally…consider:  No other to include 
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Did the authors identify any limitations? 
Are the conclusions the same in the 
abstract and the full text? 
 
Citation:  Marzheuser 2016 
Study Design: controlled before and after study 
1.   Does the study address a clearly focused 
question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with faecal 
incontinence secondary to 
ARM 
Persisteen 
Used other irrigation 
systems 
Functional outcomes 
2.   Was the population randomised? 
 If YES, were appropriate methods used? 
Eg: random number tables, opaque envelopes 
No 
Note: The following methods are not appropriate: 
alternating participants coin toss, birth dates, record 
numbers, days of the week 
 
3. Was allocation to intervention or comparator groups 
concealed? 
No 
Is it possible for those allocating to know which 
group they are allocating people to?  
As above, methods such as alternating participants 
coin toss, birth dates, record numbers, days of the 
week will not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators blinded to group 
allocation? If NO, was assessment of outcomes 
blinded? 
No 
5. Were interventions (and comparisons) well 
described and appropriate? 
Aside from the intervention, were the groups treated 
equally? 
Was exposure to intervention and comparison 
adequate? 
Was contamination acceptably low? 
Yes 
6. Was ethical approval sought and received? 
Do the authors report this? 
Not stated 
7. Was a trial protocol published?  
Was a protocol published in a journal or clinical trial 
registry before participants were recruited?  
If a protocol is available, are the outcomes reported 
in the paper listed in the protocol? 
Not stated 
 
8. Were the groups similar at the start of the trial? I:C – n=2:1; only 
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Are baseline characteristics provided and discussed 
(eg age, sex, social class, life style etc.)?  
Are any differences >10%? 
compared by ARM 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, for which 
outcome? 
Were there sufficient participants? 
Small sample 
(n=40persisteen, 18 
control) not clear if all 
possible patients recruited 
10. Were participants properly accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to which they 
were randomised?  
Was an Intention to Treat analysis conducted? 
Was the follow-up period long enough? 
median follow-up 3 years 
(1-4) 
11. Data analysis 
Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
controlled for; How loss to follow-up was 
addressed. 
reasonable 
12. Results 
Were outcome measures reliable (eg objective or 
subjective measures)?  
Were all outcome measurements complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately supported 
by the results? 
Subjective measures so 
potential for recall bias 
13.  Is any sponsorship/conflict of interest reported? Yes, none 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the abstract and the 
full text? 
Yes, small study 
 
 
Citation:  Midrio 2016 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly focused 
question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with ARM 
Persiteen 
None 
Bowel function, QoL 
2.   Was the population randomised? 
 If YES, were appropriate methods used? 
Eg: random number tables, opaque envelopes 
Not applicable 
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Note: The following methods are not appropriate: 
alternating participants coin toss, birth dates, record 
numbers, days of the week 
 
3. Was allocation to intervention or comparator 
groups concealed? 
Not applicable 
Is it possible for those allocating to know which group 
they are allocating people to?  
As above, methods such as alternating participants 
coin toss, birth dates, record numbers, days of the 
week will not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators blinded to 
group allocation? If NO, was assessment of outcomes 
blinded? 
Not applicable 
5. Were interventions (and comparisons) well 
described and appropriate? 
Aside from the intervention, were the groups treated 
equally? 
Was exposure to intervention and comparison 
adequate? 
Was contamination acceptably low? 
Well described, no 
detail if other methods 
also used 
6. Was ethical approval sought and received? 
Do the authors report this? 
Not reported 
7. Was a trial protocol published?  
Was a protocol published in a journal or clinical trial 
registry before participants were recruited?  
If a protocol is available, are the outcomes reported in 
the paper listed in the protocol? 
Not reported 
8. Were the groups similar at the start of the trial? 
Are baseline characteristics provided and discussed 
(eg age, sex, social class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, for which 
outcome? 
Were there sufficient participants? 
Small sample (n=78), 
not clear if all potential 
patients approached, 
multi-center 
10. Were participants properly accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to which they 
3 month follow-up  
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were randomised?  
Was an Intention to Treat analysis conducted? 
Was the follow-up period long enough? 
11. Data analysis 
Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
controlled for; How loss to follow-up was addressed. 
reasonable 
12. Results 
Were outcome measures reliable (eg objective or 
subjective measures)?  
Were all outcome measurements complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately supported by 
the results? 
No validated Italian 
questionnaire for bowel 
function so one was 
designed  
13.  Is any sponsorship/conflict of interest reported? Yes, none 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the abstract and the 
full text? 
Lack of validated 
questionnaire, small 
sample 
 
Citation:  Nasher 2014 
Study Design: uncontrolled before and after 
1.   Does the study address a clearly focused 
question/hypothesis 
Yes/Can't tell/No 
Population/Problem? 
Intervention? 
Comparator/control? 
Outcomes? 
Can you identify the primary outcome? 
Children with faecal 
incontinence, patients 
with NBD excluded) 
Persisteen 
None (before and after) 
Bowel function using FC 
scoring system 
2.   Was the population randomised? 
 If YES, were appropriate methods used? 
Eg: random number tables, opaque envelopes 
Not applicable 
Note: The following methods are not appropriate: 
alternating participants coin toss, birth dates, record 
numbers, days of the week 
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3. Was allocation to intervention or comparator 
groups concealed? 
Not applicable 
Is it possible for those allocating to know which group 
they are allocating people to?  
As above, methods such as alternating participants 
coin toss, birth dates, record numbers, days of the 
week will not allow appropriate allocation 
concealment. 
 
4.  Were participants/investigators blinded to 
group allocation? If NO, was assessment of outcomes 
blinded? 
Not applicable 
5. Were interventions (and comparisons) well 
described and appropriate? 
Aside from the intervention, were the groups treated 
equally? 
Was exposure to intervention and comparison 
adequate? 
Was contamination acceptably low? 
Reasonable description, 
no details if other 
additional methods 
used. 
6. Was ethical approval sought and received? 
Do the authors report this? 
Not reported 
7. Was a trial protocol published?  
Was a protocol published in a journal or clinical trial 
registry before participants were recruited?  
If a protocol is available, are the outcomes reported in 
the paper listed in the protocol? 
Not reported 
8. Were the groups similar at the start of the trial? 
Are baseline characteristics provided and discussed 
(eg age, sex, social class, life style etc.)?  
Are any differences >10%? 
Not applicable 
9.    Was the sample size sufficient? 
Were there enough participants?   
Was there a power calculation? If YES, for which 
outcome? 
Were there sufficient participants? 
13 self –selected to 
enrol in study with 3 
excluded, data for 10 
patients 
10. Were participants properly accounted for? 
Was follow-up ≥ 80%?   
Were patients analysed in the groups to which they 
were randomised?  
Was an Intention to Treat analysis conducted? 
Was the follow-up period long enough? 
Mean follow-up 21.1 
months 
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11. Data analysis 
Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
controlled for; How loss to follow-up was addressed. 
Adequate 
12. Results 
Were outcome measures reliable (eg objective or 
subjective measures)?  
Were all outcome measurements complete?  
Were all important outcomes assessed? 
Are the authors' conclusions adequately supported by 
the results? 
Validated scoring 
system used to assess 
bowel function and 
social issues, potential 
for recall bias but 
unavoidable. 
13.  Is any sponsorship/conflict of interest reported? Yes, none 
14.  Finally…consider:  
Did the authors identify any limitations? 
Are the conclusions the same in the abstract and the 
full text? 
Participants self-
selected, possible that 
more motivated and 
compliant to use 
Peristeen  
 
Citation:  Pacilli 2014 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
Is the study design clearly stated? 
Consider if retrospective or prospective 
Not clearly stated but 
identified as 
retrospective case 
series 
Does the study address a clearly focused question? 
Consider: population and outcomes (are these 
appropriate?) 
Children with faecal 
incontinence or 
constipation 
Satisfaction, presence 
of side effects 
 
Are the setting, locations and relevant dates provided? 
Consider: recruitment period; follow-up & data 
collection. 
Yes, 2007 – 2012, 
median follow up 2 
years 
Are there explicit inclusion/exclusion criteria? Not stated 
Were patients enrolled consecutively? Retrospective review 
not clear who selected 
for Peristeen use 
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Are participant characteristics provided? 
Consider if: sufficient details; a baseline table is 
included. 
yes 
Are outcome measures appropriate?  
Consider if: the methods of assessment are valid & 
reliable. 
Not stated that validated 
questionnaire used to 
collect data 
Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
considered/controlled for. 
Only numbers and 
percentages used 
Is information provided on participant flow?  
Consider if following provided: flow diagram; numbers 
of participants at each stage; details of drop-outs; 
details of missing participant data; follow-up time 
summarised; numbers of outcome events. 
4/23 had stopped using 
but not clear when 
stopped using 
Are the results well described? 
Consider if: effect sizes, confidence intervals/standard 
deviations provided; the results support the 
conclusions and are they the same in the abstract and 
the full text. 
Lacking detail, 9/23 also 
using oral laxatives 
Is any sponsorship/conflict of interest reported? Not reported 
Finally…Did the authors identify any limitations and, if 
so, are they captured above? 
Small sample 
 
 
